Podcasts about american epilepsy society

Despite advances in epilepsy management, disparities and lack of inclusion of many people with epilepsy are associated with increased morbidity and mortality. Improving awareness and promoting diversity in research participation can advance treatment for underserved populations and improve trust. In this episode, Teshamae Monteith, MD, PhD, FAAN speaks Dave F. Clarke, MBBS, FAES, author of the article “Diversity and Underserved Patient Populations in Epilepsy,” in the Continuum® February 2025 Epilepsy issue. Dr. Monteith is a Continuum® Audio interviewer and an associate editor of Continuum® Audio and an associate professor of clinical neurology at the University of Miami Miller School of Medicine in Miami, Florida. Dr. Clarke is the Kozmetsky Family Foundation Endowed Chair of Pediatric Epilepsy and Chief or Comprehensive Pediatric Epilepsy Center, Dell Medical School at the University of Texas at Austin in Austin, Texas. Additional Resources Read the article: Diversity and Underserved Patient Populations in Epilepsy Subscribe to Continuum: shop.lww.com/Continuum Earn CME (available only to AAN members): continpub.com/AudioCME Continuum® Aloud (verbatim audio-book style recordings of articles available only to Continuum® subscribers): continpub.com/Aloud More about the American Academy of Neurology: aan.com Social Media facebook.com/continuumcme @ContinuumAAN Host: @HeadacheMD Full episode transcript available here Dr Jones: This is Dr Lyell Jones, Editor-in-Chief of Continuum, the premier topic-based neurology clinical review and CME journal from the American Academy of Neurology. Thank you for joining us on Continuum Audio, which features conversations with Continuum's guest editors and authors who are the leading experts in their fields. Subscribers to the Continuum Journal can read the full article or listen to verbatim recordings of the article and have access to exclusive interviews not featured on the podcast. Please visit the link in the episode notes for more information on the article, subscribing to the journal, and how to get CME. Dr Monteith: This is Dr Teshamae Monteith. Today I'm interviewing Dr Dave Clarke about his article on diversity and underserved patient populations in epilepsy, which appears in the February 2025 Continuum issue on epilepsy. So why don't you introduce yourself to our audience? Dr Clarke: Sure. My name is Dr Dave Clarke, as alluded to. I'm presently at the University of Texas in Austin, originating from much farther south. I'm from Antigua, but have been here for quite a while working within the field in epilepsy surgery, but more and more getting involved in outreach, access to care, and equity of healthcare in epilepsy. Dr Monteith: And how did you get involved in this kind of work? Dr Clarke: That's an amazing question. You know, I did it in a bit of a inside out fashion. I initially started working in the field and trying to get access to persons in the Caribbean that didn't have any neurological care or investigative studies, but very quickly realized that persons around the corner here in Texas and wherever I've worked have had the exact same problems, getting access via fiscal or otherwise epilepsy care, or geographically getting access, with so few having neurologists close at hand. Therefore, I started working both on a regional, national, and it transcended to a global scale. Dr Monteith: Wow, so you're just everywhere. Dr Clarke: Well, building bridges. I've found building bridges and helping with knowledge and garnering knowledge, you can expand your reach without actually moving, which is quite helpful. Dr Monteith: Yeah. So why don't you tell us why you think this work is so important in issues of diversity, underserved populations, and of course, access to epilepsy care? Dr Clarke: Sure, not a problem. And I think every vested person in this can give you a different spiel as to why they think it's important. So, I'll add in a few facts pertaining to access, but also tell you about why I think personally that it's not only important, but it will improve care for all and improve what you believe you could do for a patient. Because the sad thing is to have a good outcome in the United States presently, we have over three hundred epilepsy centers, but they have about eight or nine states that don't have any epilepsy centers at all. And even within states themselves, people have to travel up to eight hours, i.e., in Texas, to get adequate epilepsy care. So that's one layer. Even if you have a epilepsy center around the corner, independent of just long wait times, if you have a particular race or ethnicity, we've found out that wait may be even longer or you may be referred to a general practitioner moreso than being referred to an epilepsy center. Then you add in layers of insurance or lack thereof, which is a big concern regardless of who you are; poverty, which is a big concern; and the layers just keep adding more. Culture, etcetera, etcetera. If you could just break down some of those barriers, it has been shown quite a few years ago that once you get to an epilepsy center, you can negate some of those factors. You can actually reduce time to access and you can improve care. So, that's why I'm so passionate about this, because something could potentially be done about it. Dr Monteith: That's cool. So, it sounds like you have some strategies, some strategies for us. Dr Clarke: Indeed. And you know, this is a growth and this is a learning curve for me and will be for others. But I think on a very local, one-to-one scale, the initial strategy I would suggest is you have to be a good listener. Because we don't know how, when, where or why people are coming to us for their concerns. And in order to judge someone, if they may not have had a follow-up visit or they may not have gotten to us after five medications, the onus may not have been on that person. In other words, as we learned when we were in medical school, history is extremely important, but social history, cultural history, that's also just as important when we're trying to create bridges. The second major thing that we have to learn is we can't do this alone. So, without others collaborating with us outside of even our fields, the social worker who will engage, the community worker who will discuss the translator for language; unless you treat those persons with respect and engage with those persons to help you to mitigate problems, you'll not get very far. And then we'll talk about more, but the last thing I'll say now is they have so many organizations out there, the Institute of Medicine or the International League Against Epilepsy or members of the American Epilepsy Society, that have ways, ideas, papers, and articles that can help guide you as to how better mitigate many of these problems. Dr Monteith: Great. So, you already mentioned a lot of things. What are some things that you feel absolutely the reader should take away in reading your article? You mentioned already listening skills, the importance of interdisciplinary work, including social work, and that there are strategies that we can use to help reduce some of this access issues. But give me some of the essential points and then we'll dive in. Dr Clarke: OK. I think first and foremost we have to lay the foundation in my mind and realize what exactly is happening. If you are Native American, of African descent, Hispanic, Latinx, geographically not in a region where care can be delivered, choosing one time to epilepsy surgery may be delayed twice, three, four times that of someone of white descent. If you are within certain regions in the US where they may have eight, nine, ten, fourteen epilepsy centers, you may get to that center within two to three years. But if you're in an area where they have no centers at all, or you live in the Dakotas, it may be very difficult to get to an individual that could provide that care for you. That's very, very basic. But a few things have happened a few years ago and even more recently that can help. COVID created this groundswell of ambulatory engagement and ambulatory care. I think that can help to mitigate time to get into that person and improving access. In saying that, there are many obstacles to that, but that's what we have to work towards: that virtual engagement and virtual care. That would suggest in some instances to some persons that it will take away the one-to-one care that you may get with persons coming to you. But I guarantee that you will not lose patients because of this, because there's too big a vacuum. Only 22% of persons that should actually get to epilepsy centers actually get to epilepsy centers. So, I think we can start with that foundation, and you can go to the article and learn a lot more about what the problems are. Because if you don't know what the problems are, you can't come up with solutions. Dr Monteith: Just give us a few of the most persistent inequities and epilepsy care? Dr Clarke: Time to seeing a patient, very persistent. And that's both a disparity, a deficiency, and an inequity. And if you allow me, I'll just explain the slight but subtle difference. So, we know that time to surgery in epilepsy in persons that need epilepsy surgery can be as long as seventeen years. That's for everyone, so that's a deficiency in care. I just mentioned that some sociodemographic populations may not get the same care as someone else, and that's a disparity between one versus the other. Health equity, whether it be from NIH or any other definition, suggests that you should get equitable care between one person and the other. And that brings in not only medical, medicolegal or potential bias, that we may have one person versus the other. So, there's a breakdown as to those different layers that may occur. And in that I'm telling you what some of the potential differences are. Dr Monteith: And so, you mentioned, it comes up, race and ethnicity being a major issue as well as some of the geographic factors. How does that impact diagnosis and really trying to care for our patients? Dr Clarke: So again, I'm going to this article or going to, even. prior articles. It has been shown by many, and most recently in New Jersey, that if you're black, Hispanic, Latin- Latinx, it takes you greater than two times the time to surgery. Reduced time to surgery significantly increases morbidity. It potentially increases mortality, as has been shown by a colleague of mine presently in Calgary. And independent of that, we don't look at the other things, the other socially related things. Driving, inability to work, inability to be adequately educated, the stigma related to that in various cultures, various countries. So, that deficit not only increased the probability of having seizures, but we have to look at the umbrella as to what it does. It significantly impacts quality of life of that individual and, actually, the individuals around them. Dr Monteith: So, what are some of these drivers, and how can we address them, or at least identify them, in our clinic? Dr Clarke: That's a question that's rather difficult to answer. And not because there aren't ideas about it, but there's actually mitigating those ideas or changing those ideas we're just presently trying to do. Although outlines have been given. So, in about 2013, the federal government suggested outlines to improve access and to reduce these inequities. And I'll just give you a few of them. One of those suggestions was related to language and having more improved and readily available translators. Something simple, and that could actually foster discussions and time to better management. Another suggestion was try to train more persons from underserved populations, persons of color. Reason being, it has been shown in the social sciences and it is known in the medical sciences that, if you speak to a person of similar culture, you tend to have a better rapport, you tend to be more compliant, and that track would move forward, and it reduces bias. Now we don't have that presently, and I'm not sure if we'll have that in the near future, although we're trying. So then, within your centers, if you have trainings on cultural sensitivity, or if you have engagements and lectures about how you can engage persons from different populations, those are just some very simple pearls that can improve care. This has been updated several times with the then-Institute of Medicine in 2012, 2013, they came out with, in my mind, a pretty amazing article---but I'm very biased---in which they outline a number of strategic initiatives that could be taken to improve research, improve clinical care, improve health equity through health services research, to move the field forward, and to improve overall care. They updated this in 2020, and it's a part of the 2030 federal initiative not only for epilepsy, but to improve overarching care. All of this is written in bits and pieces and referenced in the article. To add icing on top, the World Health Organization, through advocacy of neurological groups as well as the International League Against Epilepsy and the AES, came out with the Intersectoral Action Plan on Epilepsy and Other Neurological Diseases, which advocates for parallel improvement in overall global care. And the United States have signed on to it, and that have lit a fire to our member organizations like the American Epilepsy Society, American Academy of Neurology, and others, trying to create initiatives to address this here. I started off by saying this was difficult because, you know, we have debated epilepsy care through 1909 when the International League against Epilepsy was founded, and we have continually come up with ways to try and advance care. But this have been the most difficult and critical because there's social dynamics and social history and societal concerns that have negated us moving forward in this direction. But fortunately, I think we're moving in that direction presently. That's my hope. And the main thing we have to do is try to sustain that. Dr Monteith: So, you talked about the importance of these global initiatives, which is huge, and other sectors outside of neurology. Like for example, technology, you spoke about telemedicine. I think you were referring to telemedicine with COVID. What other technologies that are more specific to the field of epilepsy, some of these monitorings that maybe can be done? Dr Clarke: I was just going to just going to jump on that. Thank you so much for asking. Dr Monteith: I have no disclosures in this field. I think it's important and exciting to think how can we increase access and even access to monitoring some of these technologies. That might be expensive, which is another issue, but…. Dr Clarke: So, the main things in epilepsy diagnosis and management: you want to hear from the patient history, you want to see what the seizures look like, and then you want to find ways in which to monitor those seizures. Hearing from the patient, they have these questionnaires that have been out there, and this is local, regional, global, many of them standardized in English and Spanish. Our colleagues in Boston actually created quite a neat one in English and Spanish that some people are using. Ecuador has one. We have created someone- something analogous. And those questionnaires can be sent out virtually and you can retrieve them. But sometimes seeing is believing. So, video uploads of seizures, especially the cell phone, I think has been management-changing for the field of epilepsy. The thing you have to do however, is do that in a HIPAA-compliant way. And several studies are ongoing. In my mind, one of the better studies here was done on the East Coast, but another similar study, to be unnamed, but again, written out in the articles. When you go into these apps, you can actually type in a history and upload a video, but the feed is not only going to you, it may be going to the primary care physician. So, it not only helps in one way in you educating the patient, but you educate that primary care physician and they become extenders and providers. I must add here my colleagues, because we can't do without them. Arguably in some instances, some of the most important persons to refer patients, that's the APPs, the PAs and the nurse practitioners out there, that help to refer patients and share patients with us. So, that's the video uploads they're seeing. But then the other really cool part that we're doing now is the ambulatory world of EEGs. Ceribell, Zeto, to name of few, in which you could potentially put the EEG leads on persons with or without the EEG technologist wirelessly and utilize the clouds to review the EEGs. It's not perfect just yet, but that person that has to travel eight hours away from me, if I could do that and negate that travel when they don't have money to pay for travel or they have some potential legal issues or insurance-related issues and I could read the EEG, discuss with them via telemedicine their care, it actually improves access significantly. I'm going to throw in one small twist that, again, it's not perfect. We're now trying to monitor via autonomic features, heart rate movement and others, for seizures and alert family members, parents, because although about 100,000 people may be affected with epilepsy, we're talking about 500,000 people who are also affected that are caregivers, affiliates, husbands, wives, etcetera. Just picture it: you have a child, let's say three, four years old and every time they have a seizure- or not every time, but 80% of times when they have a seizure, it alerts you via your watch or it alerts you in your room. It actually gives that child a sense of a bit more freedom. It empowers you to do something about it because you can understand here. It potentially negates significant morbidity. I won't stretch it to say SUDEP, but hopefully the time will come when actually it can prevent not only morbidity, but may prevent death. And I think that's the direction we are going in, to use technology to our benefit, but in a HIPAA-compliant way and in a judicious way in order to make sure that we not only don't overtreat, but at the end of the day, we have the patient as number one, meaning everything is vested towards that patient and do no harm. Dr Monteith: Great. One thing you had mentioned earlier was that there are even some simple approaches, efficiency approaches that we can use to try and optimize care for all in our clinics. Give me what I need to know, or do. Give me what I need to do. Dr Clarke: Yeah, I'll get personal as to what we're trying to do here, if you don't mind. The initial thing we did, we actually audited care and time to care delivery. And then we tried to figure out what we could do to improve that access and time to care, triaging, etcetera. A very, very simple thing that can be done, but you have to look at costs, is to have somebody that actually coordinates getting persons in and out of your center. If you are a neurologist that works in private practice, that could potentially be a nurse being associated directly one-and-one with one of the major centers, a third- or fourth-level center. That coordination is key. Educate your nurses about epilepsy care and what the urgent situations are because it will take away a lot of your headache and your midnight calls because they'll be able to know what to do during the day. Video uploads, as I suggested, regardless of the EMR that you have, figure out a way that a family could potentially send a video to you, because that has significantly helped in reducing investigative studies. Triaging appropriately for us to know what patients we can and cannot see. Extenders has helped me significantly, and that's where I'll end. So, as stated, they had many neurologists and epileptologists, and utilizing appropriately trained nurse practitioners or residents, engaging with them equally, and/or social workers and coordinators, are very helpful. So hopefully that's just some low-hanging fruit that can be done to improve that care. Dr Monteith: So why don't you give us some of your major takeaways to how we can improve epilepsy care for all people? Dr Clarke: I've alluded to some already, but I like counts of threes and fives. So, I think one major thing, which in my mind is a major takeaway, is cultural sensitivity. I don't think that can go too far in improving care of persons with epilepsy. The second thing is, if you see a patient that have tried to adequately use medications and they're still having seizures, please triage them. Please send them to a third- or fourth-level epilepsy center and demand that that third- or fourth-level epilepsy center communicate with you, because that patient will eventually come back and see you. The third thing---I said three---: listen to your patients. Because those patients will actually help and tell you what is needed. And I'm not only talking about listening to them medication-wise. I know we have time constraints, but if you can somehow address some of those social needs of the patients, that will also not only improve care, but negate the multiple calls that you may get from a patient. Dr Monteith: You mentioned a lot already. This is really wonderful. But what I really want to know is what you're most hopeful about. Dr Clarke: I have grandiose hopes, I'll tell you. I'll tell you that from the beginning. My hope is when we look at this in ten years and studies are done to look at equitable care, at least when it comes to race, ethnicity, insurance, we'll be able to minimize, if not end, inequitable care. Very similar to the intersectoral action plan in epilepsy by 2030. I'll tell you something that suggests, and I think it's global and definitely regional, the plan suggests that 90% of persons with epilepsy should know about their epilepsy, 80% of persons with epilepsy should be able to receive appropriate care, and 70% of persons with epilepsy should have adequately controlled epilepsy. 90, 80, 70. If we can get close to that, that would be a significant achievement in my mind. So, when I'm chilling out in my home country on a fishing boat, reading EEGs in ten years, if I can read that, that would have been an achievement that not necessarily I would have achieved, but at least hopefully I would have played a very small part in helping to achieve. That's what I think. Dr Monteith: Awesome. Dr Clarke: I appreciate you asking me that, because I've never said it like that before. In my own mind, it actually helped with clarity. Dr Monteith: I ask great questions. Dr Clarke: There you go. Dr Monteith: Thank you so much. I really- I really appreciate your passion for this area. And the work that you do it's really important, as you mentioned, on a regional, national, and certainly on a global level, important to our patients and even some very simple concepts that we may not always think about on a day-to-day basis. Dr Clarke: Oh, I appreciate it. And you know, I'm always open to ideas. So, if others, including listeners, have ideas, please don't hesitate in reaching out. Dr Monteith: I'm sure you're going to get some messages now. Dr Clarke: Awesome. Thank you so much. Dr Monteith: Thank you. I've been interviewing Dr Dave Clarke about his article on diversity and underserved patient populations in epilepsy, which appears in the most recent issue of Continuum on epilepsy. Be sure to check out Continuum Audio episodes from this and other issues. And thank you to our listeners for joining today. Dr Monteith: This is Dr Teshamae Monteith, Associate Editor of Continuum Audio. If you've enjoyed this episode, you'll love the journal, which is full of in-depth and clinically relevant information important for neurology practitioners. Use this link in the episode notes to learn more and subscribe. AAN members, you can get CME for listening to this interview by completing the evaluation at continpub.com/audioCME. Thank you for listening to Continuum Audio.

Emergency treatment may be necessary after a person's first seizure or at the onset of abnormal acute repetitive (cluster) seizures; it is required for status epilepticus. Treatment for these emergencies is dictated by myriad clinical factors and informed by published guidance as well as emerging research.   In this episode, Lyell K. Jones, MD, FAAN, speaks with David G. Vossler, MD, FAAN, FACNS, FAES, author of the article “First Seizures, Acute Repetitive Seizures, and Status Epilepticus,” in the Continuum® February 2025 Epilepsy issue. Dr. Jones is the editor-in-chief of Continuum: Lifelong Learning in Neurology® and is a professor of neurology at Mayo Clinic in Rochester, Minnesota. Dr. Vossler a clinical professor of neurology at the University of Washington School of Medicine in Seattle, Washington. Additional Resources Read the article: First Seizures, Acute Repetitive Seizures, and Status Epilepticus Subscribe to Continuum: shop.lww.com/Continuum Earn CME (available only to AAN members): continpub.com/AudioCME Continuum® Aloud (verbatim audio-book style recordings of articles available only to Continuum® subscribers): continpub.com/Aloud More about the American Academy of Neurology: aan.com Social Media facebook.com/continuumcme @ContinuumAAN Host: @LyellJ  Full episode transcript available here Dr Jones: This is Dr Lyell Jones, Editor-in-Chief of Continuum, the premier topic-based neurology clinical review and CME journal from the American Academy of Neurology. Thank you for joining us on Continuum Audio, which features conversations with Continuum's guest editors and authors who are the leading experts in their fields. Subscribers to the Continuum journal can read the full article or listen to verbatim recordings of the article and have access to exclusive interviews not featured on the podcast. Please visit the link in the episode notes for more information on the article, subscribing to the journal, and how to get CME. Dr Jones: This is Dr Lyell Jones, Editor-in-Chief of Continuum: Lifelong Learning in Neurology. Today, I'm interviewing Dr Dave Vossler, who has recently authored an article on emergent seizure management, taking care of patients with the first seizure, acute repetitive seizures, and status epilepticus, which is an article in our latest issue of Continuum covering all topics related to epilepsy. Dr Vossler is a neurologist at the University of Washington, where he's a clinical professor of neurology and has an active clinical and research practice in epileptology. Dr Vossler, welcome. Thank you for joining us today. Why don't you introduce yourself to our listeners? Dr Vossler: Thank you very much for the introduction, Lyell. It's a pleasure to speak with you on this podcast, and I hope to go over a lot of important new information in the management of seizure emergencies. As you said, I'm a clinical professor in neurology at University of Washington, been in medicine for many decades now and have published and done research in this area. So, I'm anxious to give you not only my academic experience, but also talk about my own management of patients with status epilepticus over the last four decades. Dr Jones: Yeah, that's fantastic. And I always appreciate hearing from experienced clinicians, and I think our readers and our listeners do appreciate that voice of clinical expertise. And I'll tell you this is a topic, you know, as a neurologist who doesn't see many patients with acute seizure emergencies in my own practice, I think this is a topic that gives many clinicians, including neurologists, some anxiety. Your article, Dr Vossler, is really chock-full of helpful and clinically relevant considerations in the acute management of seizures. So, you now have the full attention of a huge audience of mostly neurologists. What's the one most important practice change that you would like to see in the care of patients with either first or acute prolonged seizures? Dr Vossler: Without a doubt, the most important clinical takeaway with regard to the status epilepticus---and for status epilepticus, many, many clinical trials, research trials have been done over the last couple decades and they all consistently show the same thing, that by and large most patients who have status epilepticus are underdosed and undertreated and treated too slowly in the initial stages of the status epilepticus. And it's important to use full bolus dosages of benzodiazepines to prevent mortality, morbidity, and later disability of these patients. To prevent the respiratory depression, many physicians are afraid to use higher doses of benzodiazepines, even guideline-recommended doses of benzodiazepines for fear of respiratory depression. But it's actually counterintuitive. It turns out that most cases of respiratory depression are due to inadequate doses and due to the status epilepticus itself. We know there's greater mortality, we know there's greater morbidity and we know that there's greater need for higher dose, subsequent, anti-seizure medications, prolonged status, if we don't use the proper doses. So, we'll kind of go over that a little bit, but that is the one clinical takeaway that I really would like our listeners to have. Dr Jones: Let's follow that thread a little bit. Dave, I know obviously we will speak in hypotheticals here. We're not going to talk about actual patients, but I think we've all been in the clinical situation where you have a patient who comes into the emergency room usually who's actively seizing, unknown history, don't know much about the patient, don't know much about the circumstances of the onset of the seizure. But we now have a patient with prolonged convulsive seizures. How do we walk through that? What are the first steps in the management of that patient? Dr Vossler: Yeah, well, I'll try to be brief for the purposes of the podcast. We do, of course, go through all of that in detail in the Continuum article, which hopefully everybody will look at very carefully. Really in the first table, the very first table of the article, I go through the recommended guideline for the American Epilepsy Society on the management of what we call established status epilepticus. The scenario you're talking about is just exactly that: established status epilepticus. It's not sort of evolving or developing status. We're okay they're having a few seizures and we're kind of getting there. No, this patient is now having evidence of convulsive seizure activity and it's continuing or it's repeated seizures without recovery. And so, the first phase is definitely a benzodiazepine and then the second phase is then a longer-acting bolus of a drug like phosphenotoine, valproic acid or levetiracetam. I could get into the details about dosing of the benzodiazepines, but maybe I'll let you guide me on whether we wanted to get into that kind of detail right at the outset. It's going to be a little bit different. For children, its weight-based dosing, but for adults, whether you use lorazepam or you use diazepam or you use midazolam, the doses are a little bit different. But they are standardized, and gets back to this point that I made earlier, we're acting too slow. We're not getting these patients quick enough, for various reasons, and the doses that are most commonly used are below what the guidelines call for. Dr Jones: That's great to know, and I think it's fine for the details to refer our listeners to the article because there are great details in there about a step-by-step approach to the established status epilepticus. The nomenclature and the definitions have evolved, haven't they, Dr Vossler, over time? Refractory status epilepticus, new-onset refractory status epilepticus, super refractory status epilepticus. Tell us about those entities, how they're distinguished and how you approach those. Dr Vossler: That's an important thing to kind of go over. They- in 2015, the International League Against Epilepsy, ILAE, which is, again, our international organization that guides our understanding of all kinds of things epileptic in nature around the world. In 2015 they put out a definition of status epilepticus, but it used to be that patients had thirty minutes of continuous seizure activity or repetitive obvious motor seizures with impairment of awareness and they don't recover impairment between these seizures. And that goes on for thirty minutes. That was the old definition of status epilepticus. Now, the operational definition is five minutes. And I think that's key to understand that, after five minutes of this kind of overt seizure activity, you need to intervene. And that's what's called T1 in the 2015 guideline, the international guideline. There are a bunch of different axes in the classification of status that talk about semiology, etiology, EEG patterns, and what age group you're talking about. We won't really get into those in the Continuum article because that's really more detailed than a clinician really should be. Needing to think about the stages, what we call the stages of status epilepticus that you mentioned and I alluded to earlier are important. And that is sort of new nomenclature, and I think probably general neurologists and most emergency room physicians aren't familiar with those. So, it just briefly goes through those. Developing status epilepticus is where you're starting- the patient's starting to have more frequent seizures, and it's heading essentially in the wrong direction, if you will. Established status epilepticus, as I mentioned, is, you know, this seizure act, convulsive or major, major outward overt seizure activity lasting five minutes or more, at which time therapy needs to begin. Again, getting back to my point, what doesn't happen often enough is we're not- we're intervening too late. Third is refractory status epilepticus, which refers to status epilepticus which continues despite adequate doses of an initial benzodiazepine given parenterally followed by a full loading dose of a single non-sedating anti-seizure medicine, which today includes phosphenotoine IV valproic acid or IV levetiracetam. In the United States, and increasingly around the world, people really are using levetiracetam. First, it has some advantages. There's now proof from a class one NIH-funded trial. We know that these three drugs are equivalent at the full doses that I go over in the article. You have your kind of dealer's choice on those. Phenobarbital, which we used to use and I used as a resident as long as forty years ago, is really a second choice drug because of its sedating and other side effects. But around the world in resource-poor countries phenobarbital can be used and, in a pinch, certainly is an appropriate drug. And then finally, you mentioned super refractory status epilepticus and that's status that's persisting for more than twenty four hours. Now, despite initial benzo and non-sedating anti-seizure medicine, but also lasting more than twenty four hours while receiving an intravenous infusional sedating, anesthetizing anti-seizure medicine like ketamine, propofol, pentobarbital or midazolam drips. Dr Jones: So, it sounds like the definitions have evolved in a way that improves the outcomes, right? To do earlier identification of status epilepticus and more aggressive management, I think that's a great takeaway. If we move all the way to the other end of the spectrum, let's move to the ambulatory setting and we have a patient who comes in and they've had one seizure, they're an adult; one seizure, the first seizure. The key question is, how do we anticipate the risk of future seizures? But walk us through how you talk to that patient, how you evaluate that patient to decide if and when to start anti-seizure medicines. Dr Vossler: Well, it depends a little bit if it's an adult or a child, but the decision making process and the data behind it is pretty robust now. And the decision making process is pretty similar for adults and children, with some differences which I can talk about. First of all, first seizures. I think it's really important to stress that there's been so much research in this area. I'd like to get a cross point that they're not as innocuous as I think many general neurologists might suspect. We know that there is a two- to threefold increased risk of death in children and adults following a first seizure. Moreover, the risk of a second seizure, both in kids and adults, is about 36% two years after that first seizure. It's about 46% five years after that first seizure. It's really pretty substantial. The risk of a second seizure is increased twofold. It doubled in the presence of any kind of a history of prior brain insults that could result in seizures. Could be infections, it could be a prior stroke, it could be prior significant brain trauma. It's also doubled in the presence of an EEG, which shows epileptiform discharges like spikes and sharp waves---and not just a sort of borderline things like sharply contoured rhythmic Theta activity. That's really not what we're talking about. We're talking about overt epileptiform discharges. It's doubled in the presence of lesion that can be seen on imaging studies, and it's doubled in the presence of seizures if that first seizure occurs during sleep. So, we have a number of things that double the risks, above the risk of a second seizure, above that 36% at two years and 46% at five years that I spoke about. And so those things need to be considered when you're counseling a patient about that. Should you be on an anti-seizure medicine after that first seizure? Specifically, to the point of anti-seizure medications, the guideline that was done, the 2015 guideline that was done by the American Academy of Neurology for adults, and the 2003 guideline was actually a practice parameter that was done by the Academy and the American Epilepsy Society for children, are really kind of out of date. They talk about the adverse effects of anti-seizure medications, but when you look back at the studies that were included in developing that practice parameter for kids and guidelines for adults, they are the old drugs: carbamazepine, phenytoin, phenobarbital and valproate. Well, I don't think I need to tell this audience, this well-educated audience, that we don't use those drugs anymore. We are using more modern anti-seizure medicines that have been developed since 1995; things like lamotrigine, levetiracetam, and lecosamide. Those three in particular have very low adverse events. So, the guideline that the Academy, American Academy Neurology and American Epilepsy Society put together for kids and for adults talks about this high adverse event profile. And so, you need to take a look at the risks that I talked about of a seizure recurrence and balance that against adverse effects. But I'm here to tell you that the newer anti-seizure medicines---and by newer I'm talking in the last thirty years since lamotrigine was approved in 1995---these drugs have much better side effect profiles. And I think all epileptologists would agree with that. They're not necessarily more effective, but they are better tolerated. That makes the discussion of the risk of a second seizure, the risk of mortality versus side effects of drugs, it really pushes the risk category higher on the first side and not on the side of drugs. We know that if you take an anti-seizure medicine, you reduce your risk of a second seizure by half. Now, that's not sustained over five years, but over the first two years, you've reduced it by half. In a person who's driving, needs to get to work, has to take the kids to school, whatever, most of my patients are like, yeah, okay, sign me up. These drugs are really pretty well tolerated. There's a substantial risk of a second seizure. So, I'll do that. In a kid,  a child that's, you know, not driving yet, that might be a different discussion. And the parents might say, well, I'd rather not have my son exposed, my daughter exposed to this. They're trying to go to school. They're trying to learn. We don't want to hinder that. We'll wait for a second seizure and then if they have a second seizure, which by the way is, you know, one of the definitions of epilepsy, well then they have epilepsy, then they probably will need to go on the seizure medication. Dr Jones: Great summary, Dr Vossler, and it is worth our audience being aware that the evidence has evolved alongside the improvement in the adverse effect profile. And sounds like your threshold is a little lower to treat then maybe it would have been some time ago, right? Dr Vossler: I would say that's exactly correct in my opinion. Particularly for adults, absolutely. Dr Jones: That's fantastic, Dr Vossler. I imagine there are a lot of aspects of caring for these patients that are challenging, and I imagine many scenarios are actually pretty rewarding. What do you find the most rewarding aspect of caring for patients with acute seizure management? Dr Vossler: Yes, I mean, that is really true. I would say that the most challenging things are treating refractory status epilepticus, but worse yet, new onset refractory status epilepticus and the super refractory status epilepticus, which I talk extensively about or write extensively about in the article and provide a lot of guidance on. Really, those conditions are so challenging because they can go on for such a long time. Patients are hospitalized for a long time. A lot of really good clinical guidance doesn't exist yet. There is a tremendous amount of research in that area which I find exciting, and really there's an amazing amount of international research on that, I think most of our audience probably is unaware of. And certainly, with those conditions, there is a high risk of later disability and mortality. We go through all of that in the article. The rewards really come from helping these people. When someone was super refractory status and it were non- sorry, new onset refractory status epilepticus, has been in the hospital for thirty days, it gets really hard for everybody; the family, the patient. And for us, it wears on us. Yet when they walk out the door, and I've had these people come back to the epilepsy clinic and see me later. We're managing their anti-seizure medications. They've survived. The NORSE patients often have substantial disability. They have cognitive and memory and even some psychiatric disability. But yet we can help them. It's not just management in the hospital, but it's getting to know these people, and I take them from the hospital and see them in my clinic and manage them long-term. I get a lot of great satisfaction out of that. We're hoping to do even better, stop patients' status early and get them to recover with no sequelae. Dr Jones: What a great visual, seeing those patients who have a devastating problem and they come back to clinic and you get the full circle. And what a great place to end. Dr Vossler, thank you so much for joining us, and thank you for such a thorough and fascinating discussion on the importance of understanding and managing patients with the first seizure, acute repetitive seizures, and status epilepticus. Dr Vossler: Thank you very much, Lyell. Dr Jones: Again, we've been speaking with Dr Dave Vossler, author of an article on emergent seizure management, first seizures, acute repetitive seizures and status epilepticus in Continuum's most recent issue on epilepsy. Please check it out, and thank you to our listeners for joining today. Dr Monteith: This is Dr Teshamae Monteith, Associate Editor of Continuum Audio. If you've enjoyed this episode, you'll love the journal, which is full of in-depth and clinically relevant information important for neurology practitioners. Use this link in the episode notes to learn more and subscribe. AAN members, you can get CME for listening to this interview by completing the evaluation at continpub.com/audioCME. Thank you for listening to Continuum Audio.

A recent practice guideline provides updated evidence-based conclusions and recommendations regarding in utero effects of anti-seizure medications and folic acid supplementation on the prevalence of major congenital malformations, adverse perinatal outcomes, and neurodevelopmental outcomes. Dr. Parthvi Ravat interviewed Dr. Alison Pack about the guideline, which was produced by the American Academy of Neurology, American Epilepsy Society, and Society for Maternal-Fetal Medicine.Review the practice guideline: Teratogenesis, perinatal, and neurodevelopmental outcomes after in utero exposure to antiseizure medication (Neurology, May 2024)Other studies mentioned in the episode: Risk of major congenital malformations and exposure to antiseizure medication monotherapy (JAMA Neurology, March 2024) Sharp Waves episodes are meant for informational purposes only, and not as clinical or medical advice.Let us know how we're doing: podcast@ilae.org.The International League Against Epilepsy is the world's preeminent association of health professionals and scientists, working toward a world where no person's life is limited by epilepsy. Visit us on Facebook, X (Twitter), Instagram, and LinkedIn.

Una crisis febril en un niño puede ser aterrador, lo más importante es saber cuándo buscar atención médica después de una convulsión febril. Para hablar de este tema más a fondo y conocer las diferencias entre crisis febriles y otro tipo de convulsiones en niños, nos acompaña el Dr. Guillermo Abdón Villegas en este episodio de Pediatras en Línea. El Dr. Abdón Villegas es pediatra y neurólogo pediátrico peruano, actualmente realizando un diploma en EEG pediátrico en el Hospital Infantil de México Federico Gómez (HIMFG). Se graduó en Pediatría en el Instituto Nacional de Salud del Niño de Breña, de Neurología Pediátrica del HIMFG avalado por la UNAM, y es bachiller en Biología por la Universidad Nacional de San Agustín de Arequipa (UNSA). Ha recibido capacitación extensa en epilepsia pediátrica, principalmente por la ILAE, la American Epilepsy Society, y la European Pediatric Neurology Society, y es miembro de diversas sociedades médicas especializadas. Su carrera está enfocada en mejorar el diagnóstico y tratamiento de trastornos neurológicos en niños, con un enfoque particular en aplicar conocimientos avanzados en Perú, donde existe una gran necesidad de especialistas en epilepsia pediátrica. Además, está comprometido con la docencia para contribuir al desarrollo de la próxima generación de neuropediatras en su país. Instagram: abdon_neuropedia ¿Tienes algún comentario sobre este episodio o sugerencias de temas para un futuro podcast? Escríbenos a pediatrasenlinea@childrenscolorado.org.

MedLink Neurology Podcast is delighted to feature selected episodes from BrainWaves, courtesy of James E Siegler MD, its originator and host. BrainWaves is an academic audio podcast whose mission is to educate medical providers through clinical cases and topical reviews in neurology, medicine, and the humanities, and episodes originally aired from 2016 to 2021. Originally released: November 13, 2017 How often do you call the plumber and say, "My faucet is leaking," and then the plumber REMOVES your faucet? Problem solved, right? Ironically, this simplistic approach works extremely well in a variety of epileptic conditions. In this week's show, Dr. Myriam Abdennadher and Danielle Becker comment on the protocol and efficacy for surgery in patients with drug-resistant epilepsy. Produced by James E. Siegler. Music by Little Glass Men, Montplaisir, Three Chain Links, and Squire Tuck. Voiceover by Isa Smrstik. BrainWaves' podcasts and online content are intended for medical education only and should not be used for clinical decision-making. REFERENCESDeGiorgio CM, Krahl SE. Neurostimulation for drug-resistant epilepsy. Continuum (Minneap Minn) 2013;19(3 Epilepsy):743-55. PMID 23739108Engel J Jr, Wiebe S, French J, et al. Practice parameter: temporal lobe and localized neocortical resections for epilepsy: report of the Quality Standards Subcommittee of the American Academy of Neurology, in association with the American Epilepsy Society and the American Association of Neurological Surgeons. Neurology 2003;60(4):538-47. Erratum in: Neurology 2003;60(8):1396. PMID 12601090Englot DJ, Wang DD, Rolston JD, Shih TT, Chang EF. Rates and predictors of long-term seizure freedom after frontal lobe epilepsy surgery: a systematic review and meta-analysis. J Neurosurg 2012;116(5):1042-8. PMID 22304450Jobst BC, Cascino GD. Resective epilepsy surgery for drug-resistant focal epilepsy: a review. JAMA 2015;313(3):285-93. PMID 25602999Schwartz TH, Spencer DD. Strategies for reoperation after comprehensive epilepsy surgery. J Neurosurg 2001;95(4):615-23. PMID 11596956Spencer S, Huh L. Outcomes of epilepsy surgery in adults and children. Lancet Neurol 2008;7(6):525-37. PMID 18485316 We believe that the principles expressed or implied in the podcast remain valid, but certain details may be superseded by evolving knowledge since the episode's original release date.

In this episode, Dr. Amy Valent and guest Dr. Sarah Osmundson discuss the updated guidelines from the American Academy of Neurology on Teratogenesis, Perinatal, and Neurodevelopmental Outcomes After In Utero Exposure to Antiseizure Medication. These guidelines, developed in collaboration with the American Epilepsy Society and SMFM, provide evidence-based recommendations on anti-seizure medications, perinatal outcomes, and neurodevelopmental impacts for people with epilepsy of childbearing potential. The episode emphasizes the importance of preconception planning and appropriate medication management, addressing the complexities of epilepsy in pregnancy, including congenital malformations and neurodevelopmental outcomes. Tune in to gain valuable insights into the latest recommendations for managing epilepsy in pregnancy. Additional Resources: Practice Guidelines from the AAN, AES, and SMFM Full transcript can be found here. 

L'épilepsie est l'une des conditions neurologiques les plus fréquemment rencontrées en pédiatrie. Toutefois, naviguer parmi les différentes options de traitement n'est pas chose facile. Quelles sont les particularités de l'épilepsie chez l'enfant et comment optimiser le suivi des antiépileptiques? Pour répondre à ces questions, Trait pharmacien reçoit Geneviève Laflamme, pharmacienne au CHU de Québec, vice-présidente (secrétaire) du Regroupement de pharmaciens experts en pédiatrie de l'A.P.E.S. et détentrice de la certification américaine en pharmacie pédiatrique du BPS. Les pharmaciens membres de l'A.P.E.S. peuvent obtenir des unités de formation continue (UFC) pour l'écoute de Trait pharmacien en réussissant un questionnaire d'évaluation des apprentissages disponible sur le portail Erudis. Références : Site Web de la International League Against Epilepsy : https://www.ilae.org/ Site Web de la American Epilepsy Society : https://aesnet.org/ Glauser TA, Cnaan A, Shinnar S et coll. Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy. N Engl J Med 2010;362(9):790-9. Sharpe C, Reiner GE, Davis SL et coll. Levetiracetam versus phenobarbital for neonatal seizures: A randomized controlled trial. Pediatrics 2020;145(6):e20193182. Site Web de la formation « Épilepsie pédiatrique : osez vous impliquer » de la Faculté de pharmacie de l'Université Laval : https://www.pha.ulaval.ca/formation-continue/formations-disponibles/epilepsie-pediatrique-osez-vous-impliquer

Are people who have their first seizure during sleep at greater or lesser risk for future seizures, compared with people who have their first seizure when they're awake? Dr. Laurent Sheybani interviews Dr. Elaine Pang, author of a 2023 paper in Epilepsia that analyzed data from 1,312 adults visiting a first-seizure clinic.This episode also discusses a 2015 evidence-based guideline on managing a first unprovoked seizure in adults. The guideline was developed by the American Academy of Neurology and the American Epilepsy Society. Support the showSharp Waves episodes are meant for informational purposes only, and not as clinical or medical advice.The International League Against Epilepsy is the world's preeminent association of health professionals and scientists, working toward a world where no person's life is limited by epilepsy. Visit us on Facebook, Twitter, and Instagram.

Dr. Temitayo Oyegbile Chidi is the Chair of the Board of Directors of the National Sleep Foundation. She is also a member of the American Academy of Sleep Medicine and the American Epilepsy Society. Dr. Oyegbile Chidi is one of the country's foremost experts on sleep disorders in children. In this episode we will explore children's sleep hygiene.

"You've gotta take a pause for a second and make sure your foundation is solid before you start stacking things on top of it!" In this episode, our guest Nicole Rodriguez stresses the importance of learning to pause and calibrate your work with the goals you're working toward. She also shares insight on the value of taking the time to learn to do something the right way from the start.Bio:Nicole Rodriguez is a people-loving marketing professional who has worked in just about every industry and marketing role. She has found her place in the association space, thriving in roles on small, scrappy teams. Currently a marketing team of one, Nicole is responsible for everything marketing and communications; from brand management to promotion of her organization's programs and events. Nicole enjoys mission-driven work, spending time with her family, and volunteering in her community. When not wearing her marketing hat, she's wearing a hard hat—currently restoring a 1957 home in South Florida.Guest Links:Nicole's Linkedin profile: (https://www.linkedin.com/in/nmerod/)American Epilepsy Society: (https://www.aesnet.org/)Additional Links:State of Nonprofit Marketing report: (https://www.feathr.co/nonprofit-marketing-statistics)Playlist:Now That We Found Love by Heavy DThe King of Wishful Thinking by Go WestAnything by the Backstreet Boys***Hosted by the brilliant team at Feathr (https://www.feathr.co/).Feathr is the nonprofit marketing platform designed to help mission and member-based organizations build purposeful connections with their community to grow impact with confidence.

In this week's episode of "Pushing the Limits I had the privilege of interview world renown cancer researcher Professor Thomas Seyfried the author of over 150 peer reviewed publications and the author of the book "Cancer as a Metabolic Disease"   For 30 years Professor Seyfried has been in the trenches as a geneticist and biochemist studying cancer cells and working out the intricacies of how to stop them proliferating. He says there are two primary fuels that cancer cells use in their abhorrent metabolism, Glucose and Glutamine and that if we can cut the fuel supply of these two things to the cancer cells we have a powerful non toxic way of killing cancer cells. He and colleagues designed the Press-pulse: a novel therapeutic strategy for the metabolic management of cancer and in this interview we dive into his latest research and what you can do if you have cancer or want to lower your chances of getting cancer.   If you enjoyed this episodes make sure to check out our Ebook/Interview series "What Your Oncologist isn't telling you" Ebook  with 20 world leading experts on this approach and adjunct therapies.   People can donate to Professor Seyfried's crucial work via this link the https://foundationformetaboliccancertherapies.com/   Dr Thomas Seyfried Bio Thomas N. Seyfried received his Ph.D. in Genetics and Biochemistry from the University of Illinois, Urbana, in 1976. He did his undergraduate work at the University of New England, where he recently received the distinguished Alumni Achievement Award. He also holds a Master's degree in Genetics from Illinois State University. Thomas Seyfried served with distinction in the United States Army's First Cavalry Division during the Vietnam War and received numerous medals and commendations. He was a Postdoctoral Fellow in the Department of Neurology at the Yale University School of Medicine and then served on the faculty as an Assistant Professor in Neurology. Other awards and honors have come from such diverse organizations as the American Oil Chemists Society, the National Institutes of Health, The American Society for Neurochemistry, the Ketogenic Diet Special Interest Group of the American Epilepsy Society, the Academy of Comprehensive and Complementary Medicine, and the American College of Nutrition. Dr. Seyfried previously served as Chair, Scientific Advisory Committee for the National Tay-Sachs and Allied Diseases Association and presently serves on several editorial boards, including those for Nutrition & Metabolism, Neurochemical Research, the Journal of Lipid Research, and ASN Neuro, where he is a Senior Editor. Dr. Seyfried has over 150 peer-reviewed publications and is the author of the book, Cancer as a Metabolic Disease: On the Origin, Management, and Prevention of Cancer(Wiley, 1st ed., 2012).   Health Optimisation and Life Coaching with Lisa Tamati Lisa offers solution focused coaching sessions to help you find the right answers to your challenges. Topics Lisa can help with:  Lisa is a Genetics Practitioner, Health Optimisation Coach, High Performance and Mindset Coach. She is a qualified Ph360 Epigenetics coach and a clincian with The DNA Company and has done years of research into brain rehabilitation, neurodegenerative diseases and biohacking. She has extensive knowledge on such therapies as hyperbaric oxygen,  intravenous vitamin C, sports performance, functional genomics, Thyroid, Hormones, Cancer and much more. Testing Options Comprehensive Thyroid testing DUTCH Hormone testing Adrenal Testing Organic Acid Testing Microbiome Testing Cell Blueprint Testing Epigenetics Testing DNA testing Basic Blood Test analysis She can help you navigate the confusing world of health and medicine and can advocate for you. She can also advise on the latest research and where to get help if mainstream medicine hasn't got the answers you are searching for whether you are facing challenges from cancer to gut issues, from depression and anxiety, weight loss issues, from head injuries to burn out.: Consult with Lisa    Join our Patron program and support the show Pushing the Limits' has been free to air for over 8 years. Providing leading edge information to anyone who needs it. But we need help on our mission.  Please join our patron community and get exclusive member benefits (more to roll out later this year) and support this educational platform for the price of a coffee or two You can join by going to  Lisa's Patron Community   Lisa's Anti-Aging and Longevity Supplements  Lisa has spent years curating a very specialised range of exclusive longevity, health optimising supplements from leading scientists, researchers and companies all around the world.  This is an unprecedented collection. The stuff Lisa wanted for her mum but couldn't get in NZ. Check out the range at her LongLifeLabs shop   Subscribe to our popular Youtube channel  with over 600 videos, millions of views, a number of full length documentaries, and much more. You don't want to miss out on all the great content on our Lisa's youtube channel. Youtube   Order Lisa's Books My latest book Relentless chronicles the inspiring journey of how my mother and I defied the odds after an aneurysm left my mum, Isobel, with massive brain damage at age 74. The medical professionals told me there was absolutely no hope of any quality of life again. Still, I used every mindset tool, years of research and incredible tenacity to prove them wrong and bring my mother back to full health within three years. Get your copy here: Lisa's Books   Our NMN Bio Flagship Longevity Range A range by molecular biologist Dr Elena Seranova NMN: Nicotinamide Mononucleotide, an NAD+ precursor Researchers have found that Nicotinamide Adenine Dinucleotide or NAD+, a master regulator of metabolism and a molecule essential for the functionality of all human cells, decreases dramatically over time.   What is NMN? NMN Bio offers a cutting edge Vitamin B3 derivative named NMN (beta Nicotinamide Mononucleotide) that can boost the levels of NAD+ in muscle tissue and liver. Take charge of your energy levels, focus, metabolism and overall health so you can live a happy, fulfilling life. Founded by scientists, NMN Bio offers supplements of the highest purity and rigorously tested by an independent, third-party lab. Start your cellular rejuvenation journey today.   Support Your Healthy Aging We offer powerful third-party tested NAD+ boosting supplements so you can start your healthy ageing journey today. Shop now: NMNBIO NMN (beta Nicotinamide Mononucleotide) 250mg | 30 capsules NMN (beta Nicotinamide Mononucleotide) 500mg | 30 capsules 6 Bottles | NMN (beta Nicotinamide Mononucleotide) 250mg | 30 Capsules 6 Bottles | NMN (beta Nicotinamide Mononucleotide) 500mg | 30 Capsules Boost Your NAD+ Levels — Healthy Ageing: Redefined Cellular Health Energy & Focus Bone Density Skin Elasticity DNA Repair Cardiovascular Health Brain Health Metabolic Health Listen to the episodes with Dr Seranova on the show: https://www.lisatamati.com/podcast--dr-elena-seranova/ https://www.lisatamati.com/podcast--dr-elena-seranova-part-3/   Perfect Amino Supplement by Dr David Minkoff Introducing PerfectAmino PerfectAmino is an amino acid supplement that is 99% utilized by the body to make protein. PerfectAmino is 3-6x the protein of other sources with almost no calories. 100% vegan and non-GMO. The coated PerfectAmino tablets are a slightly different shape and have a natural, non-GMO, certified organic vegan coating on them so they will glide down your throat easily. Fully absorbed within 20-30 minutes! No other form of protein comes close to PerfectAminos Listen to the episode with Dr MInkoff here:  Ketone Products by HVMN The world's best  exogenous Ketone IQ Listen to the episode with Dr Latt Mansor Lisa's  ‘Fierce' Sports Jewellery Collection For Lisa's gorgeous and inspiring sports jewellery collection, 'Fierce', go to Jewellery   For Vielight Device Vielight brain photobiomodulation devices combine electrical engineering and neuroscience. To find out more about photobiomodulation, current studies underway and already completed and for the devices mentioned in this video go to www.vielight.com Use code "tamati" at checkout to get a 10% discount on any of their devices.   Enjoyed This Podcast? If you did, subscribe and share it with your friends! If you enjoyed tuning in, then leave us a review and share this with your family and friends. Have any questions? You can contact my team through email (support@lisatamati.com) or find me on Facebook, Twitter, Instagram and YouTube. For more episode updates, visit my website. You may also tune in on Apple Podcasts. To pushing the limits, Lisa and team

Is There A Greater Risk Of Brain Cancer From Cell Phone Use For Younger People? Dr. Thomas Seyfried, • Contact: thomas.seyfried@bc.edu • Book – Cancer as a Metabolic Disease #ThomasSeyfried#Cancer #MetabolicDisease Dr. Thomas Seyfried, is a professor and author publishing a groundbreaking book; Cancer as a Metabolic Disease: On the Origin, Management, and Prevention of Cancer.This book addresses controversies related to the origins of cancer and provides solutions to cancer management and prevention. It expands upon Otto Warburg's well-known theory that all cancer is a disease of energy metabolism.  However, Warburg did not link his theory to the "hallmarks of cancer" and thus his theory was discredited.  This book aims to provide evidence, through case studies, that cancer is primarily a metabolic disease requiring metabolic solutions for its management and prevention.  Support for this position is derived from critical assessment of current cancer theories.  Brain cancer case studies are presented as a proof of principle for metabolic solutions to disease management, but similarities are drawn to other types of cancer, including breast and colon, due to the same cellular mutations that they demonstrate. The book also provides extensive information showing that cancer can be best defined as a mitochondrial metabolic disease rather than as a genetic disease. This new concept has implications for the development of new non-toxic cancer therapies including the ketogenic diet. Experts in the cancer research field have praised this comprehensive study as one of science's hottest topics. Dr. Thomas Seyfried received his Ph.D. in Genetics and Biochemistry from the University of Illinois, Urbana. He did his undergraduate work at the University of New England, where he recently received the distinguished Alumni Achievement Award. He has a Master's degree in Genetics from Illinois State University.  Thomas Seyfried served with distinction in the United States Army's during the Vietnam War and received numerous medals and commendations. He was a Postdoctoral Fellow in the Department of Neurology at the Yale University School of Medicine and then served on the faculty as an Assistant Professor in Neurology. Other awards and honors have come from such diverse organizations as the American Oil Chemists Society, the National Institutes of Health, The American Society for Neurochemistry, and the Ketogenic Diet Special Interest Group of the American Epilepsy Society.  Dr. Seyfried previously served as Chair, Scientific Advisory Committee for the National Tay-Sachs and Allied Diseases Association and presently serves on several editorial boards, including those for Nutrition & Metabolism, Neurochemical Research, the Journal of Lipid Research, and ASN Neuro, where he is a Senior Editor.  Dr. Seyfried has over 150 peer-reviewed publications and is the author of the book “Cancer as a Metabolic Disease: On the Origin, Management, and Prevention of Cancer (Wiley Press).” To Contact Dr Thomas N. Seyfried, Ph.D. email:  thomas.seyfried@bc.edu Disclaimer:Medical and Health information changes constantly. Therefore, the information provided in this podcast should not be considered current, complete, or exhaustive. Reliance on any information provided in this podcast is solely at your own risk. The Real Truth About Health does not recommend or endorse any specific tests, products, procedures, or opinions referenced in the following podcasts, nor does it exercise any authority or editorial control over that material. The Real Truth About Health provides a forum for discussion of public health issues. The views and opinions of our panelists do not necessarily reflect those of The Real Truth About Health and are provided by those panelists in their individual capacities. The Real Truth About Health has not reviewed or evaluated those statements or claims. 

ONCE UPON A GENE - EPISODE 188 How Being a Mom to Twins with a Rare and Undiagnosed Condition Has Shaped Rare Mom, Scientist and Co-Founder of the MAST Genes Research Foundation with Dr. Kim Aldinger Dr. Kim Aldinger is a Seattle Children's scientist that studies how genes influence brain development and how those processes malfunction to cause neurodevelopmental disorders. She's also a mom to rare twins, Chloe and Grayson. EPISODE HIGHLIGHTS Tell us about your twins, Chloe and Grayson. They are seven years old, fraternal twins, but wildly different. I had a surprise twin pregnancy and they were born early. Both were in the NICU, but Grayson had some lingering concerns like a low grade temperature and fussiness. He began having seizures, going into status epilepticus, and he was on a lot of medication and machines for breathing support. Chloe didn't have signs of symptoms like Grayson, but as a twin, she had a brain MRI and they found evidence of an intraventricular hemorrhage.  What diagnosis did you receive from whole exome sequencing? We had whole exome sequencing because we thought there was a biochemical event that had initiated the seizures Grayson was experiencing. The testing came back negative, but part of what I do professionally is analyze exome sequencing, so I requested the data from the report and I didn't see anything that explained what was causing his seizures. When he was three years old, Grayson's sequencing results were re-evalutated. MAST4, associated with a brain disorder, was reported to be of uncertain significance based on literature that linked MAST4 to epilepsy.  You're changing the focus of your scientific studies. Can you talk about that? My background is in brain development and genetics and I've mostly spent my time in a human genetics lab. Part of what I do is look at genes and figure out how they are or are not working and how that impacts brain development, specifically the cerebellum, which is responsible for motor coordination and sensory integration. The MAST4 gene isn't related to the cerebellum region, so through research to learn more, a project was born. Thanks to the American Epilepsy Society, we received a small grant to work more on the MAST4 research work.  CONNECT WITH KIM Twitter https://twitter.com/kaaldinger?lang=en Email kimberly.aldinger@seattlechildrens.org LINKS & RESOURCES MENTIONED CTNNB1 Connect and Cure Conference https://www.curectnnb1.org/ COMBINEDBrain https://combinedbrain.org/ American Epilepsy Society https://aesnet.org/ MAST Genes Research Foundation https://mastgenes.org/ TUNE INTO THE ONCE UPON A GENE PODCAST Spotify https://open.spotify.com/show/5Htr9lt5vXGG3ac6enxLQ7 Apple Podcasts https://podcasts.apple.com/us/podcast/once-upon-a-gene/id1485249347 Stitcher https://www.stitcher.com/podcast/once-upon-a-gene Overcast https://overcast.fm/itunes1485249347/once-upon-a-gene CONNECT WITH EFFIE PARKS Website https://effieparks.com/ Twitter https://twitter.com/OnceUponAGene Instagram https://www.instagram.com/onceuponagene.podcast/?hl=en Built Ford Tough Facebook Group https://www.facebook.com/groups/1877643259173346/ Interested in advertising on Once Upon a Gene? Email advertising@bloodstreammedia.com for more information!

Is It Safe For People With Cancer To Eat Fruit And Beans? Dr. Thomas Seyfried, • Contact: thomas.seyfried@bc.edu • Book – Cancer as a Metabolic Disease #ThomasSeyfried#Cancer #MetabolicDisease Dr. Thomas Seyfried, is a professor and author publishing a groundbreaking book; Cancer as a Metabolic Disease: On the Origin, Management, and Prevention of Cancer.This book addresses controversies related to the origins of cancer and provides solutions to cancer management and prevention. It expands upon Otto Warburg's well-known theory that all cancer is a disease of energy metabolism.  However, Warburg did not link his theory to the "hallmarks of cancer" and thus his theory was discredited.  This book aims to provide evidence, through case studies, that cancer is primarily a metabolic disease requiring metabolic solutions for its management and prevention.  Support for this position is derived from critical assessment of current cancer theories.  Brain cancer case studies are presented as a proof of principle for metabolic solutions to disease management, but similarities are drawn to other types of cancer, including breast and colon, due to the same cellular mutations that they demonstrate. The book also provides extensive information showing that cancer can be best defined as a mitochondrial metabolic disease rather than as a genetic disease. This new concept has implications for the development of new non-toxic cancer therapies including the ketogenic diet. Experts in the cancer research field have praised this comprehensive study as one of science's hottest topics. Dr. Thomas Seyfried received his Ph.D. in Genetics and Biochemistry from the University of Illinois, Urbana. He did his undergraduate work at the University of New England, where he recently received the distinguished Alumni Achievement Award. He has a Master's degree in Genetics from Illinois State University.  Thomas Seyfried served with distinction in the United States Army's during the Vietnam War and received numerous medals and commendations. He was a Postdoctoral Fellow in the Department of Neurology at the Yale University School of Medicine and then served on the faculty as an Assistant Professor in Neurology. Other awards and honors have come from such diverse organizations as the American Oil Chemists Society, the National Institutes of Health, The American Society for Neurochemistry, and the Ketogenic Diet Special Interest Group of the American Epilepsy Society.  Dr. Seyfried previously served as Chair, Scientific Advisory Committee for the National Tay-Sachs and Allied Diseases Association and presently serves on several editorial boards, including those for Nutrition & Metabolism, Neurochemical Research, the Journal of Lipid Research, and ASN Neuro, where he is a Senior Editor.  Dr. Seyfried has over 150 peer-reviewed publications and is the author of the book “Cancer as a Metabolic Disease: On the Origin, Management, and Prevention of Cancer (Wiley Press).” To Contact Dr Thomas N. Seyfried, Ph.D. email:  thomas.seyfried@bc.edu Disclaimer:Medical and Health information changes constantly. Therefore, the information provided in this podcast should not be considered current, complete, or exhaustive. Reliance on any information provided in this podcast is solely at your own risk. The Real Truth About Health does not recommend or endorse any specific tests, products, procedures, or opinions referenced in the following podcasts, nor does it exercise any authority or editorial control over that material. The Real Truth About Health provides a forum for discussion of public health issues. The views and opinions of our panelists do not necessarily reflect those of The Real Truth About Health and are provided by those panelists in their individual capacities. The Real Truth About Health has not reviewed or evaluated those statements or claims. 

RARE MAMAS RISING- EPISODE 26 Driving Discoveries with Principal Investigator at the Center for Integrative Brain Research at Seattle Children's Research Institute, Assistant Professor in the Department of Pediatrics, Division of Genetic Medicine at the University of Washington & Rare Mama Dr. Kim Aldinger   Dr. Aldinger is a Principal Investigator in the Center for Integrative Brain Research at Seattle Children's Research Institute and an Assistant Professor in the Department of Pediatrics, Division of Genetic Medicine at The University of Washington. She received a BA in biology from Brandeis University, an ALM in psychology from Harvard University, and a Ph.D. in neurobiology from The University of Chicago. Dr. Aldinger has over 20 years of research experience applying neuroscience and genomics techniques to understand the impact of genetic changes on the development of brain structures and functions relevant to neurodevelopmental disorders. She is also the mom of twins Chloe and Grayson. Grayson has a rare genetic disease called MAST4. Dr. Aldinger understands the impact of a rare disease from both a professional, scientific perspective and a personal parent viewpoint. Her deep roots in research, coupled with her passion to contribute to the rare disease community, make her one to watch as she helps drive discoveries!  EPISODE HIGHLIGHTS Dr. Aldinger's path to becoming a brain researcher  The work Dr. Aldinger does as a Professor of Genetic Medicine and as a Principal Investigator  Grayson's diagnostic journey and MAST4 diagnosis  How Dr. Aldinger co-founded the MAST Genes Research Foundation and the work she's doing on MAST genetic mutations How being a mom to a child with a rare condition informs Dr. Aldinger's work  Advice for rare parents on how to approach research Dr. Aldinger's best learnings for fellow rare mamas   LINKS & RESOURCES MENTIONED   Kimberly Aldinger https://www.seattlechildrens.org/research/centers-programs/integrative-brain-research/our-labs/aldinger-lab/ Twitter: https://twitter.com/kaaldinger MAST Genes Research Foundation  Website: https://mastgenes.org/ Facebook: https://www.facebook.com/groups/780432716601479 Twitter: https://twitter.com/mastgenes     Seattle Children's Research Institute https://www.seattlechildrens.org/research/   The University of Washington  https://www.peds.uw.edu/specialties/genetic-medicine   American Epilepsy Society https://aesnet.org/   Global Genes https://globalgenes.org/ CONNECT WITH NIKKI   Facebook https://www.facebook.com/RareMamas1/ Instagram https://www.instagram.com/Rare_Mamas/ Website https://raremamas.com/ Email info@raremamas.com

MedLink Neurology Podcast is delighted to feature selected episodes from BrainWaves, courtesy of James E Siegler MD, its originator and host. BrainWaves is an academic audio podcast whose mission is to educate medical providers through clinical cases and topical reviews in neurology, medicine, and the humanities, and episodes originally aired from 2016 to 2021. Originally released: July 18, 2017 There's more to epilepsy than AED titration. (Shocking, I know.) Especially in women, management is undeniably complex. For example, the same enzymatic machinery used to metabolize AEDs is also used to break down estrogen-containing oral contraceptives--an interaction that could literally open a Pandora's box of complications. These and other issues affecting the management of women with epilepsy are addressed by Dr. Danielle Becker in this week's BrainWaves podcast. BrainWaves podcasts and online content are intended for medical education only and should not be used to guide medical decision-making in routine clinical practice. Any cases discussed in this episode are fictional and do not contain any patient health-identifying information. This episode was vetted and approved by Danielle Becker. REFERENCES Crawford P. Best practice guidelines for the management of women with epilepsy. Epilepsia 2005;46 Suppl 9:117-24. PMID 16302885 Harden CL, Hopp J, Ting TY, et al. Practice parameter update: management issues for women with epilepsy--focus on pregnancy (an evidence-based review): obstetrical complications and change in seizure frequency: report of the Quality Standards Subcommittee and Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and American Epilepsy Society. Neurology 2009;73(2):126-32. PMID 19398682 Herzog AG, Fowler KM, Smithson SD, et al. Progesterone vs placebo therapy for women with epilepsy: a randomized clinical trial. Neurology 2012;78(24):1959-66. PMID 22649214 Meador K, Reynolds MW, Crean S, Fahrbach K, Probst C. Pregnancy outcomes in women with epilepsy: a systematic review and meta-analysis of published pregnancy registries and cohorts. Epilepsy Res 2008;81(1):1-13. PMID 18565732 Meador KJ, Baker GA, Browning N, et al. Breastfeeding in children of women taking antiepileptic drugs: cognitive outcomes at age 6 years. JAMA Pediatr 2014;168(8):729-36. PMID 24934501 Reiter SF, Bjørk MH, Daltveit AK, et al. Life satisfaction in women with epilepsy during and after pregnancy. Epilepsy Behav 2016;62:251-7. PMID 27513352 Taubøll E, Sveberg L, Svalheim S. Interactions between hormones and epilepsy. Seizure 2015;28:3-11. PMID 25765693 Velíšková J, Desantis KA. Sex and hormonal influences on seizures and epilepsy. Horm Behav 2013;63(2):267-77. PMID 22504305  We believe that the principles expressed or implied in the podcast remain valid, but certain details may be superseded by evolving knowledge since the episode's original release date.

GBM And Other Stage 4 Cancers Should Not Be Considered Terminal If Treated With Ketogenic Metabolic Therapy Dr. Thomas Seyfried, • Contact: thomas.seyfried@bc.edu • Book – Cancer as a Metabolic Disease #ThomasSeyfried#Cancer #MetabolicDisease Dr. Thomas Seyfried, is a professor and author publishing a groundbreaking book; Cancer as a Metabolic Disease: On the Origin, Management, and Prevention of Cancer.This book addresses controversies related to the origins of cancer and provides solutions to cancer management and prevention. It expands upon Otto Warburg's well-known theory that all cancer is a disease of energy metabolism.  However, Warburg did not link his theory to the "hallmarks of cancer" and thus his theory was discredited.  This book aims to provide evidence, through case studies, that cancer is primarily a metabolic disease requiring metabolic solutions for its management and prevention.  Support for this position is derived from critical assessment of current cancer theories.  Brain cancer case studies are presented as a proof of principle for metabolic solutions to disease management, but similarities are drawn to other types of cancer, including breast and colon, due to the same cellular mutations that they demonstrate. The book also provides extensive information showing that cancer can be best defined as a mitochondrial metabolic disease rather than as a genetic disease. This new concept has implications for the development of new non-toxic cancer therapies including the ketogenic diet. Experts in the cancer research field have praised this comprehensive study as one of science's hottest topics. Dr. Thomas Seyfried received his Ph.D. in Genetics and Biochemistry from the University of Illinois, Urbana. He did his undergraduate work at the University of New England, where he recently received the distinguished Alumni Achievement Award. He has a Master's degree in Genetics from Illinois State University.  Thomas Seyfried served with distinction in the United States Army's during the Vietnam War and received numerous medals and commendations. He was a Postdoctoral Fellow in the Department of Neurology at the Yale University School of Medicine and then served on the faculty as an Assistant Professor in Neurology. Other awards and honors have come from such diverse organizations as the American Oil Chemists Society, the National Institutes of Health, The American Society for Neurochemistry, and the Ketogenic Diet Special Interest Group of the American Epilepsy Society.  Dr. Seyfried previously served as Chair, Scientific Advisory Committee for the National Tay-Sachs and Allied Diseases Association and presently serves on several editorial boards, including those for Nutrition & Metabolism, Neurochemical Research, the Journal of Lipid Research, and ASN Neuro, where he is a Senior Editor.  Dr. Seyfried has over 150 peer-reviewed publications and is the author of the book “Cancer as a Metabolic Disease: On the Origin, Management, and Prevention of Cancer (Wiley Press).” To Contact Dr Thomas N. Seyfried, Ph.D. email:  thomas.seyfried@bc.edu Disclaimer:Medical and Health information changes constantly. Therefore, the information provided in this podcast should not be considered current, complete, or exhaustive. Reliance on any information provided in this podcast is solely at your own risk. The Real Truth About Health does not recommend or endorse any specific tests, products, procedures, or opinions referenced in the following podcasts, nor does it exercise any authority or editorial control over that material. The Real Truth About Health provides a forum for discussion of public health issues. The views and opinions of our panelists do not necessarily reflect those of The Real Truth About Health and are provided by those panelists in their individual capacities. The Real Truth About Health has not reviewed or evaluated those statements or claims. 

MedLink Neurology Podcast is delighted to feature selected episodes from BrainWaves, courtesy of James E Siegler MD, its originator and host. BrainWaves is an academic audio podcast whose mission is to educate medical providers through clinical cases and topical reviews in neurology, medicine, and the humanities, and episodes originally aired from 2016 to 2021.Originally released: March 4, 2021As many as 1% of the world has epilepsy, but far more will have a seizure in their lifetime. Not everyone needs a seizure medication, some people are even harmed by them. So who warrants treatment, and what do you start with? Consider today's program an intro to antiepileptic drug decision-making. For educational purposes only, of course. Not to guide any healthcare provider's decision-making.Produced by James E Siegler. Music courtesy of Lee Rosevere, Cellophane Sam, Jon Watts, Josh Woodward, and Rafael Archangel. The opening theme was composed by Jimothy Dalton. Sound effects by Mike Koenig and Daniel Simion. Unless otherwise mentioned in the podcast, no competing financial interests exist in the content of this episode. BrainWaves' podcasts and online content are intended for medical education only and should not be used for clinical decision-making. Be sure to follow us on Twitter @brainwavesaudio for the latest updates to the podcast.REFERENCESAnonymous. Randomized clinical trial on the efficacy of antiepileptic drugs in reducing the risk of relapse after a first unprovoked tonic-clonic seizure. First Seizure Trial Group (FIR.S.T. Group). Neurology 1993;43(3 Pt 1):478-83. PMID 8450987Bouma HK, Labos C, Gore GC, Wolfson C, Keezer MR. The diagnostic accuracy of routine electroencephalography after a first unprovoked seizure. Eur J Neurol 2016;23(3):455-63. PMID 26073548Fisher RS, Acevedo C, Arzimanoglou A, et al. ILAE official report: a practical clinical definition of epilepsy. Epilepsia 2014;55(4):475-82. PMID 24730690Fountain NB. Choosing among antiepileptic drugs. Continuum (Minneap Minn) 2010;16(3 Epilepsy):121-35. PMID 22810318Hauser WA, Rich SS, Annegers JF, Anderson VE. Seizure recurrence after a 1st unprovoked seizure: an extended follow-up. Neurology 1990;40(8):1163-70. PMID 2381523Hui AC, Tang A, Wong KS, Mok V, Kay R. Recurrence after a first untreated seizure in the Hong Kong Chinese population. Epilepsia 2001;42(1):94-7. PMID 11207791Koepp MJ, Woermann FG. Imaging structure and function in refractory focal epilepsy. Lancet Neurol 2005;4(1):42-53. PMID 15620856Krumholz A, Wiebe S, Gronseth GS, et al. Evidence-based guideline: management of an unprovoked first seizure in adults: Report of the Guideline Development Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology 2015;84(16):1705-13. PMID 25901057Leone MA, Giussani G, Nolan SJ, Marson AG, Beghi E. Immediate antiepileptic drug treatment, versus placebo, deferred, or no treatment for first unprovoked seizure. Cochrane Database Syst Rev 2016;2016(5):CD007144. Update in: Cochrane Database Syst Rev 2021;5:CD007144. PMID 27150433Manjunath R, Davis KL, Candrilli SD, Ettinger AB. Association of antiepileptic drug nonadherence with risk of seizures in adults with epilepsy. Epilepsy Behav 2009;14(2):372-8. PMID 19126436Marson A, J

A Novel Therapeutic Strategy For The Metabolic Management Of Cancer Dr. Thomas Seyfried, • Contact: thomas.seyfried@bc.edu • Book – Cancer as a Metabolic Disease #ThomasSeyfried#Cancer #MetabolicDisease Dr. Thomas Seyfried, is a professor and author publishing a groundbreaking book; Cancer as a Metabolic Disease: On the Origin, Management, and Prevention of Cancer.This book addresses controversies related to the origins of cancer and provides solutions to cancer management and prevention. It expands upon Otto Warburg's well-known theory that all cancer is a disease of energy metabolism.  However, Warburg did not link his theory to the "hallmarks of cancer" and thus his theory was discredited.  This book aims to provide evidence, through case studies, that cancer is primarily a metabolic disease requiring metabolic solutions for its management and prevention.  Support for this position is derived from critical assessment of current cancer theories.  Brain cancer case studies are presented as a proof of principle for metabolic solutions to disease management, but similarities are drawn to other types of cancer, including breast and colon, due to the same cellular mutations that they demonstrate. The book also provides extensive information showing that cancer can be best defined as a mitochondrial metabolic disease rather than as a genetic disease. This new concept has implications for the development of new non-toxic cancer therapies including the ketogenic diet. Experts in the cancer research field have praised this comprehensive study as one of science's hottest topics. Dr. Thomas Seyfried received his Ph.D. in Genetics and Biochemistry from the University of Illinois, Urbana. He did his undergraduate work at the University of New England, where he recently received the distinguished Alumni Achievement Award. He has a Master's degree in Genetics from Illinois State University.  Thomas Seyfried served with distinction in the United States Army's during the Vietnam War and received numerous medals and commendations. He was a Postdoctoral Fellow in the Department of Neurology at the Yale University School of Medicine and then served on the faculty as an Assistant Professor in Neurology. Other awards and honors have come from such diverse organizations as the American Oil Chemists Society, the National Institutes of Health, The American Society for Neurochemistry, and the Ketogenic Diet Special Interest Group of the American Epilepsy Society.  Dr. Seyfried previously served as Chair, Scientific Advisory Committee for the National Tay-Sachs and Allied Diseases Association and presently serves on several editorial boards, including those for Nutrition & Metabolism, Neurochemical Research, the Journal of Lipid Research, and ASN Neuro, where he is a Senior Editor.  Dr. Seyfried has over 150 peer-reviewed publications and is the author of the book “Cancer as a Metabolic Disease: On the Origin, Management, and Prevention of Cancer (Wiley Press).” To Contact Dr Thomas N. Seyfried, Ph.D. email:  thomas.seyfried@bc.edu Disclaimer:Medical and Health information changes constantly. Therefore, the information provided in this podcast should not be considered current, complete, or exhaustive. Reliance on any information provided in this podcast is solely at your own risk. The Real Truth About Health does not recommend or endorse any specific tests, products, procedures, or opinions referenced in the following podcasts, nor does it exercise any authority or editorial control over that material. The Real Truth About Health provides a forum for discussion of public health issues. The views and opinions of our panelists do not necessarily reflect those of The Real Truth About Health and are provided by those panelists in their individual capacities. The Real Truth About Health has not reviewed or evaluated those statements or claims. 

Dr. Alexander Whiting is a neurosurgeon and director of epilepsy surgery for Allegheny Health Network's Neuroscience Institute. He specializes in state-of-the-art epilepsy treatments, including stereoelectroencephalography (SEEG), seizure focus resections, laser ablations, vagal nerve stimulation, and responsive neurostimulation. Additionally, he has clinical interests in complex spine and brain disorders, and offers a range of surgical options and interventions for these conditions. Dr. Whiting completed his residency at the Barrow Neurological Institute in Phoenix, Arizona. He completed his fellowship in epilepsy surgery at the Cleveland Clinic in Cleveland, Ohio, and was awarded the American Epilepsy Society's prestigious Young Investigator Award. Today we speak to Dr. Whiting about SEEG.

If We Target Glucose And Glutamine We Can Manage The Majority Of Cancers Dr. Thomas Seyfried, • Contact: thomas.seyfried@bc.edu • Book – Cancer as a Metabolic Disease #ThomasSeyfried#Cancer #MetabolicDisease Dr. Thomas Seyfried, is a professor and author publishing a groundbreaking book; Cancer as a Metabolic Disease: On the Origin, Management, and Prevention of Cancer.This book addresses controversies related to the origins of cancer and provides solutions to cancer management and prevention. It expands upon Otto Warburg's well-known theory that all cancer is a disease of energy metabolism.  However, Warburg did not link his theory to the "hallmarks of cancer" and thus his theory was discredited.  This book aims to provide evidence, through case studies, that cancer is primarily a metabolic disease requiring metabolic solutions for its management and prevention.  Support for this position is derived from critical assessment of current cancer theories.  Brain cancer case studies are presented as a proof of principle for metabolic solutions to disease management, but similarities are drawn to other types of cancer, including breast and colon, due to the same cellular mutations that they demonstrate. The book also provides extensive information showing that cancer can be best defined as a mitochondrial metabolic disease rather than as a genetic disease. This new concept has implications for the development of new non-toxic cancer therapies including the ketogenic diet. Experts in the cancer research field have praised this comprehensive study as one of science's hottest topics. Dr. Thomas Seyfried received his Ph.D. in Genetics and Biochemistry from the University of Illinois, Urbana. He did his undergraduate work at the University of New England, where he recently received the distinguished Alumni Achievement Award. He has a Master's degree in Genetics from Illinois State University.  Thomas Seyfried served with distinction in the United States Army's during the Vietnam War and received numerous medals and commendations. He was a Postdoctoral Fellow in the Department of Neurology at the Yale University School of Medicine and then served on the faculty as an Assistant Professor in Neurology. Other awards and honors have come from such diverse organizations as the American Oil Chemists Society, the National Institutes of Health, The American Society for Neurochemistry, and the Ketogenic Diet Special Interest Group of the American Epilepsy Society.  Dr. Seyfried previously served as Chair, Scientific Advisory Committee for the National Tay-Sachs and Allied Diseases Association and presently serves on several editorial boards, including those for Nutrition & Metabolism, Neurochemical Research, the Journal of Lipid Research, and ASN Neuro, where he is a Senior Editor.  Dr. Seyfried has over 150 peer-reviewed publications and is the author of the book “Cancer as a Metabolic Disease: On the Origin, Management, and Prevention of Cancer (Wiley Press).” To Contact Dr Thomas N. Seyfried, Ph.D. email:  thomas.seyfried@bc.edu Disclaimer:Medical and Health information changes constantly. Therefore, the information provided in this podcast should not be considered current, complete, or exhaustive. Reliance on any information provided in this podcast is solely at your own risk. The Real Truth About Health does not recommend or endorse any specific tests, products, procedures, or opinions referenced in the following podcasts, nor does it exercise any authority or editorial control over that material. The Real Truth About Health provides a forum for discussion of public health issues. The views and opinions of our panelists do not necessarily reflect those of The Real Truth About Health and are provided by those panelists in their individual capacities. The Real Truth About Health has not reviewed or evaluated those statements or claims. 

ONCE UPON A GENE - EPISODE 172 From Cancer Biologist to Rare Disease Mom - Digging Into the Data to Better Understand SCN8A with Madeleine Oudin PhD - Professor of Biomedical Engineering at Tufts Madeleine Oudin is a scientist and Tiampo Family Assistant Professor at Tufts University. Her daughter Margo has two de novo mutations in the SCN8A gene, which causes epilepsy. She's navigating life as a rare, working mom and sharing her knowledge in an understandable and accessible way for other rare parents.  EPISODE HIGHLIGHTS Can you tell us about the epilepsy conference you just attended? The SCN8 community organizes the conference for clinicians, researchers and families every year at the American Epilepsy Society meeting. There were over 35 families in attendance who have children with SCN8A and it was amazing to meet everyone in real life. What advice do you have for parents who aren't sure about attending a conference? Meeting other people has made a big difference for me and I encourage others to find their people. Going to gatherings can lead to finding resources and there's value in connecting to others and learning more about a disease. Community is everything. As a scientist and now a rare parent, how do you look through the microscope differently? The impact of genetic testing surprised me in how vital it is when it comes to rare genetic diseases. When Margo had her first seizure and had genetic testing, the results helped to connect us to community. Genetic testing is vital for families to connect them to resources. What work have you done in the SCN8A community to help other families understand the disease and advance the treatment progress? Science communication is something I'm passionate about. Since becoming a rare mom, I started an Instagram account where I explain the science of the diagnosis and break it down so the information is accessible to everyone. I recently did a webinar breaking down the different treatment strategies for SCN8A.  Can you talk about Margo's acceptance to n-Lorem? We applied with our neurologist and were accepted into the foundation to develop custom Antisense oligonucleotide (ASO) treatments. In parallel, we're doing treatments in my lab on a mouse and mouse cells, testing out different ASOs to see if we can gain any additional insights. LINKS & RESOURCES MENTIONED ONCE UPON A GENE - Episode 139 - Remember Who You Are https://effieparks.com/podcast/139-remember-who-you-are Margot_thebrave on Instagram https://www.instagram.com/margot_thebrave/ SCN8A Alliance   https://scn8aalliance.org/ American Epilepsy Society https://www.ilae.org/ The n-lorem Foundation https://www.nlorem.org/ SCN8A Unraveled https://www.youtube.com/playlist?list=PL-RngxzecxdLsaJFQyerqqfGLarDe9MUt TUNE INTO THE ONCE UPON A GENE PODCAST Spotify https://open.spotify.com/show/5Htr9lt5vXGG3ac6enxLQ7 Apple Podcasts https://podcasts.apple.com/us/podcast/once-upon-a-gene/id1485249347 Stitcher https://www.stitcher.com/podcast/once-upon-a-gene Overcast https://overcast.fm/itunes1485249347/once-upon-a-gene CONNECT WITH EFFIE PARKS Website https://effieparks.com/ Twitter https://twitter.com/OnceUponAGene Instagram https://www.instagram.com/onceuponagene.podcast/?hl=en Built Ford Tough Facebook Group https://www.facebook.com/groups/1877643259173346/ Interested in advertising on Once Upon a Gene? Email advertising@bloodstreammedia.com for more information!

MedLink Neurology Podcast is delighted to feature selected episodes from BrainWaves, courtesy of James E Siegler MD, its originator and host. BrainWaves is an academic audio podcast whose mission is to educate medical providers through clinical cases and topical reviews in neurology, medicine, and the humanities, and episodes originally aired from 2016 to 2021. Originally released: July 27, 2017 The first seizure of life is a common presentation requiring a neurology consultation. In this episode, Dr. Brian Hanrahan of the University of Pittsburgh Medical Center, discusses his approach to counseling an adult patient with a first-ever seizure, with a particular emphasis on driving safety.  Produced by James E Siegler. Music by Axletree, Josh Woodward, and Kevin McLeod. Voiceover by Emma Smrstik. BrainWaves' podcasts and online content are intended for medical education only and should not be used for clinical decision-making. Think responsibly. Podcasts are no excuse NOT to treat a patient who is seizing. REFERENCES Deutschman CS, Haines SJ. Anticonvulsant prophylaxis in neurological surgery. Neurosurgery.1985;17(3):510-7. PMID 2864654Hemphill JC, Greenberg SM, Anderson CS, et al. Guidelines for the management of spontaneous intracerebral hemorrhage: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2015;46(7):2032-60. PMID 26022637Krumholz A. Driving issues in epilepsy: past, present, and future. Epilepsy Curr 2009;9(2):31-5. PMID 19421374Krumholz A, Shinnar S, French J, Gronseth G, Wiebe S. Evidence-based guideline: management of an unprovoked first seizure in adults: Report of the Guideline Development Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology 2015;85(17):1526-7. PMID 26503589Maganti RK, Rutecki P. EEG and epilepsy monitoring. Continuum (Minneap Minn) 2013;19(3 Epilepsy):598-622. PMID 23739100Richards KC. Patient page. The risk of fatal car crashes in people with epilepsy. Neurology 2004;63(6):E12-3. PMID 15452331Smith SJ. EEG in the diagnosis, classification, and management of patients with epilepsy. J Neurol Neurosurg Psychiatry 2005;76 Suppl 2(Suppl 2):ii2-7. PMID 15961864Sofat P, Teter B, Kavak KS, Gupta R, Li P. Time interval providing highest yield for initial EEG in patients with new onset seizures. Epilepsy Res 2016;127:229-32. PMID 27639127Temkin NR, Dikmen SS, Wilensky AJ, Keihm J, Chabal S, Winn HR. A randomized, double-blind study of phenytoin for the prevention of post-traumatic seizures. N Engl J Med 1990;323(8):497-502. PMID 2115976Thompson K, Pohlmann-Eden B, Campbell LA, Abel H. Pharmacological treatments for preventing epilepsy following traumatic head injury. Cochrane Database Syst Rev 2015;2015(8):CD009900. PMID 26259048van Breemen MS, Wilms EB, Vecht CJ. Epilepsy in patients with brain tumours: epidemiology, mechanisms, and management. Lancet Neurol 2007;6(5):421-30. PMID 17434097 We believe that the principles expressed or implied in the podcast remain valid, but certain details may be superseded by evolving knowledge since the episode's original release date.

One of my favorite things to do is kick off the year with positive, inspiring individuals like Liz Lefkofsky, a philanthropist and founder of the VING project, a giving movement that empowers 14-18 year old teens to help others. In this episode, Liz takes us behind the scenes into how she established a collaborative partnership with the one and only Meghan Markle, and why they're on a mission to give 1,000 “VINGs” to uplift amazing women in need.Episode Partner: This episode is presented by Feathr. Feathr is trusted by nonprofits of all shapes and wing-spans — from the Humane Society and Meals on Wheels to IJM and the American Epilepsy Society, plus over a thousand more! Don't rely on magic to hit your goals next year. Use Feathr to elevate your digital marketing campaigns and grow impact in 2023. Join me and Noah Barnett on January 26th for a free webinar, all about creating effective re-engagement campaigns. Click here to register.In This Episode:Liz reveals why philanthropy is like “speed dating” and what stands out to her in a sea of grant applicationsHow Liz landed a dream partnership with Meghan Markle and her nonprofit organization, Archewell Foundation (in just 2 weeks!)The hilarious story of how actress and comedian Tiffany Haddish became a spokesperson for GrouponWhy standout qualities like authenticity are most important when seeking a celebrity spokesperson or brand partner to represent your nonprofitHow to get your hands dirty and join a board or committeeLiz's aspirational views of the next generation and why she firmly believes that every Fortune 500 CEO should run a non-profit for a year.Resources & LinksCheck out my $27 mini course, Visible Reach In A Week. In 30 minutes, you'll learn how to create a $3 a day ad campaign that will drive brand awareness with your supporters.Connect with Liz at liz@lff.com or on LinkedIn. She welcomes hearing from you! Learn more about VING and The Archewell Foundation. Tune in to Meghan Markle's podcast, Archetypes.Discover the selfsea app from Pure Health Exchange.Want to make Missions to Movements even better? Take a screenshot of this episode and share it on Instagram. Be sure to tag @positivequation so I can connect with you. Let's Connect! Send a DM on Instagram or LinkedIn and let us know what you think of the show! Head to YouTube for helpful digital marketing how-to videos and podcast teasers Want to book Dana as a speaker for your event? Click here!

Taylor Shanklin is THE perfect person to talk to about creative trends, branding, and marketing. As the CEO & Founder of Barlele, a brand strategy and content marketing agency, she helps mission-minded companies and nonprofits create the most interesting and powerful brands possible.Today, Taylor inspires us to audit our branding and marketing efforts from the ground up. What do you want your vibe to be? What actually matters to your audience? Is your content speaking to their aspirations and motivations? Branding and marketing are not the same thing - and they need to be thought about separately. Let's dig in.Episode Partner: This episode is presented by Feathr. Feathr is trusted by nonprofits of all shapes and wing-spans — from the Humane Society and Meals on Wheels to IJM and the American Epilepsy Society, plus over a thousand more! Don't rely on magic to hit your goals next year. Use Feathr to elevate your digital marketing campaigns and grow impact in 2023. Join me and Noah Barnett on January 26th for a free webinar, all about creating effective re-engagement campaigns. Click here to register.In This Episode:What you NEED to ask yourself if you're planning to audit your branding and marketing efforts this year.The importance of “dumbing down” your brand positioning statement to a 5-year old's level, without the jargon.How the simple act of refreshing your logo can instantly level up your credibility and professionalism (and newsflash? You don't need to invest in a 6-figure agency to get something that looks great).A behind the scenes look at how Taylor helped Alzheimer's New Jersey reimagine their social media presence by transforming their message to be more human-centric.The incredibly affordable “unlimited graphic design” service Taylor created through her off-shoot brand, Creative Shizzle. Pricing starts at just $99 per month!Why we have to have a consistent drumbeat in our branding and marketing in order to play the long game.Resources & LinksCheck out my $27 mini course, Visible Reach In A Week. In 30 minutes, you'll learn how to create a $3 a day ad campaign that will drive brand awareness with your supporters.Learn more about Barlele if you're looking for white glove branding or marketing strategy services and social media management. And check out Creative Shizzle if you need graphic design support. Connect with Taylor on LinkedIn.Tune in to Episode 19: Creating a New Revenue Stream for Your Nonprofit, with Paige Chenault of The Birthday Party Project.Want to make Missions to Movements even better? Take a screenshot of this episode and share it on Instagram. Be sure to tag @positivequation so I can connect with you. Let's Connect! Send a DM on Instagram or LinkedIn and let us know what you think of the show! Head to YouTube for helpful digital marketing how-to videos and podcast teasers Want to book Dana as a speaker for your event? Click here!

Status Epilepticus is one of the most common pediatric neurologic emergencies and requires prompt, targeted treatment to reduce patient morbidity and mortality. On this podcast, Pediatric Critical Care Physician, Dr. Renuka Mehta, Pediatric Resident Physician, Dr. Yvonne Ibe, and medical student, Emily Austin will discuss management for status epilepticus and rapid interventions that can be potentially lifesaving—because in seizure management, time is brain.  FREE CME Credit (requires sign-in):  Link Coming Soon! Thank you for listening to this episode from the Department of Pediatrics at the Medical College of Georgia. An additional thanks to Dr. Lorna Bell, Dr. George Hsu, and Dr. Rebecca Yang who provided editing and peer review of today's discussion. If you have any comments, suggestions, or feedback- you can email us at mcgpediatricpodcast@augusta.edu Remember that all content during this episode is intended for educational purposes only. It should not be used as medical advice to diagnose or treat any particular patient. Clinical vignette cases presented are based on hypothetical patient scenarios. Thank you for your support! References: Alldredge, B. K., Gelb, A. M., Isaacs, S. M., Corry, M. D., Allen, F., Ulrich, S., Gottwald, M. D., O'Neil, N., Neuhaus, J. M., Segal, M. R., & Lowenstein, D. H. (2001). A Comparison of Lorazepam, Diazepam, and Placebo for the Treatment of Out-of-Hospital Status Epilepticus. New England Journal of Medicine, 345(9), 631–637. https://doi.org/10.1056/NEJMoa002141  Chamberlain, J. M., Kapur, J., Shinnar, S., Elm, J., Holsti, M., Babcock, L., Rogers, A., Barsan, W., Cloyd, J., Lowenstein, D., Bleck, T. P., Conwit, R., Meinzer, C., Cock, H., Fountain, N. B., Underwood, E., Connor, J. T., Silbergleit, R., Neurological Emergencies Treatment Trials, & Pediatric Emergency Care Applied Research Network investigators. (2020). Efficacy of levetiracetam, fosphenytoin, and valproate for established status epilepticus by age group (ESETT): a double-blind, responsive-adaptive, randomised controlled trial. Lancet (London, England), 395(10231), 1217–1224. https://doi.org/10.1016/S0140-6736(20)30611-5  Chamberlain, J. M., Okada, P., Holsti, M., Mahajan, P., Brown, K. M., Vance, C., Gonzalez, V., Lichenstein, R., Stanley, R., Brousseau, D. C., Grubenhoff, J., Zemek, R., Johnson, D. W., Clemons, T. E., & Baren, J. (2014). Lorazepam vs Diazepam for Pediatric Status Epilepticus: A Randomized Clinical Trial. JAMA, 311(16), 1652. https://doi.org/10.1001/jama.2014.2625  Chen, J., Xie, L., Hu, Y., Lan, X., & Jiang, L. (2018). Nonconvulsive status epilepticus after cessation of convulsive status epilepticus in pediatric intensive care unit patients. Epilepsy & Behavior: E&B, 82, 68–73. https://doi.org/10.1016/j.yebeh.2018.02.008  Fine, A., & Wirrell, E. C. (2020). Seizures in Children. Pediatrics in Review, 41(7), 321–347. https://doi.org/10.1542/pir.2019-0134  Glauser, T., Shinnar, S., Gloss, D., Alldredge, B., Arya, R., Bainbridge, J., Bare, M., Bleck, T., Dodson, W. E., Garrity, L., Jagoda, A., Lowenstein, D., Pellock, J., Riviello, J., Sloan, E., & Treiman, D. M. (2016). Evidence-Based Guideline: Treatment of Convulsive Status Epilepticus in Children and Adults: Report of the Guideline Committee of the American Epilepsy Society. Epilepsy Currents, 16(1), 48–61. https://doi.org/10.5698/1535-7597-16.1.48  Hanhan, U. A., Fiallos, M. R., & Orlowski, J. P. (2001). Status epilepticus. Pediatric Clinics of North America, 48(3), 683–694. https://doi.org/10.1016/s0031-3955(05)70334-5  Kapur, J., Elm, J., Chamberlain, J. M., Barsan, W., Cloyd, J., Lowenstein, D., Shinnar, S., Conwit, R., Meinzer, C., Cock, H., Fountain, N., Connor, J. T., Silbergleit, R., & NETT and PECARN Investigators. (2019). Randomized Trial of Three Anticonvulsant Medications for Status Epilepticus. The New England Journal of Medicine, 381(22), 2103–2113. https://doi.org/10.1056/NEJMoa1905795  Lyttle, M. D., Rainford, N. E. A., Gamble, C., Messahel, S., Humphreys, A., Hickey, H., Woolfall, K., Roper, L., Noblet, J., Lee, E. D., Potter, S., Tate, P., Iyer, A., Evans, V., Appleton, R. E., Pereira, M., Hardwick, S., Messahel, S., Noblet, J., … Hobden, G. (2019). Levetiracetam versus phenytoin for second-line treatment of paediatric convulsive status epilepticus (EcLiPSE): a multicentre, open-label, randomised trial. The Lancet, 393(10186), 2125–2134. https://doi.org/10.1016/S0140-6736(19)30724-X  Raspall‐Chaure, M., Chin, R. F. M., Neville, B. G., Bedford, H., & Scott, R. C. (2007). The Epidemiology of Convulsive Status Epilepticus in Children: A Critical Review. Epilepsia, 48(9), 1652–1663. https://doi.org/https://doi.org/10.1111/j.1528-1167.2007.01175.x  Riviello, J. J., Ashwal, S., Hirtz, D., Glauser, T., Ballaban-Gil, K., Kelley, K., Morton, L. D., Phillips, S., Sloan, E., Shinnar, S., American Academy of Neurology Subcommittee, & Practice Committee of the Child Neurology Society. (2006). Practice parameter: diagnostic assessment of the child with status epilepticus (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Neurology, 67(9), 1542–1550. https://doi.org/10.1212/01.wnl.0000243197.05519.3d  Sánchez Fernández, I., Abend, N. S., Agadi, S., An, S., Arya, R., Brenton, J. N., Carpenter, J. L., Chapman, K. E., Gaillard, W. D., Glauser, T. A., Goodkin, H. P., Kapur, K., Mikati, M. A., Peariso, K., Ream, M., Riviello, J., Tasker, R. C., & Loddenkemper, T. (2015). Time from convulsive status epilepticus onset to anticonvulsant administration in children. Neurology, 84(23), 2304–2311. https://doi.org/10.1212/WNL.0000000000001673  Trinka, E., Cock, H., Hesdorffer, D., Rossetti, A. O., Scheffer, I. E., Shinnar, S., Shorvon, S., & Lowenstein, D. H. (2015). A definition and classification of status epilepticus--Report of the ILAE Task Force on Classification of Status Epilepticus. Epilepsia, 56(10), 1515–1523. https://doi.org/10.1111/epi.13121  Welch, R. D., Nicholas, K., Durkalski-Mauldin, V. L., Lowenstein, D. H., Conwit, R., Mahajan, P. V., Lewandowski, C., Silbergleit, R., & Neurological Emergencies Treatment Trials (NETT) Network Investigators. (2015). Intramuscular midazolam versus intravenous lorazepam for the prehospital treatment of status epilepticus in the pediatric population. Epilepsia, 56(2), 254–262. https://doi.org/10.1111/epi.12905 

What happens when you combine the genius of Ryan Reynolds, David Griner (Adweek's International Editor and Host of the Adweek Podcast), and Dionna Dorsey Calloway (Founder of District of Clothing)? Together, they co-founded an incredible nonprofit called The Creative Ladder, focused on making creative industries more reflective of the communities they serve, while connecting, inspiring and elevating a new generation of creative leaders.Today, I am honored to speak with Dionna about the launch of The Creative Ladder, its mission, and more importantly, how we can ALL play a part in changing the future of the creative industry together. Episode Partner: This episode is presented by Feathr. Feathr is trusted by nonprofits of all shapes and wing-spans — from the Humane Society and Meals on Wheels to IJM and the American Epilepsy Society, plus over a thousand more! Don't rely on magic to hit your goals next year. Use Feathr to elevate your digital marketing campaigns and grow impact in 2023. Join me and Noah Barnett on January 26th for a free webinar, all about creating effective re-engagement campaigns. Click here to register.In This Episode:How a chance invitation to Adweek's Brandweek led Dionna to connect with Ryan Reynolds and David GrinerDionna shares a behind the scenes look at what it was like to launch The Creative Ladder at the Cannes Film FestivalThe power of intimate events and why The Creative Ladder focused on these tracks at their bootcamp: Advancement, Authenticity, and FocusHow we can help recruit the next generation of creative talent from underrepresented communitiesWhy having a strong sense of self leads to maximum creative outputThe importance of making connections (including how I landed a senior position at a top PR agency through a LinkedIn message!)Resources & LinksCheck out The Creative Ladder and follow them on Instagram at @creativeladderorg, along with their sister organization, Group Effort Initiative. And see what co-founder Ryan Reynolds wants you to know about his nonprofit in this short video.Check out my $27 mini course, Visible Reach In A Week. In 30 minutes, you'll learn how to create a $3 a day ad campaign that will drive brand awareness with your supporters.Want to make Missions to Movements even better? Take a screenshot of this episode and share it on Instagram. Be sure to tag @positivequation so I can connect with you. 

Dr. Andres Kanner is one of the best known researchers in the behavioral aspects of epilepsy, and has authored more than 300 papers and book chapters. Dr. Kanner sat down with ILAE to talk about his original goal of becoming an artist, his path to epileptology, and how he has worked to become what patients call "an amazing, compassionate doctor".He is director of the University of Miami School of Medicine's Comprehensive Epilepsy Center of Excellence, chief of the Epilepsy Division, and professor of clinical neurology. Dr. Kanner is quadruple-boarded in neurology, psychiatry, clinical neurophysiology and epilepsy. He has long-standing research interests in the areas of pharmacology of epilepsy, psychiatric aspects of epilepsy and surgical treatment of treatment-resistant focal epilepsy. He has served on the editorial boards of several journals and held leadership positions in many organizations, including the International League Against Epilepsy, American Epilepsy Society, and American Academy of Neurology.  The International League Against Epilepsy invites you to explore the ILAE Academy: Interactive, practice based online courses for health care professionals who diagnose and treat epilepsy. Find more information at ilae-academy.org. Support the showSharp Waves episodes are meant for informational purposes only, and not as clinical or medical advice.The International League Against Epilepsy is the world's preeminent association of health professionals and scientists, working toward a world where no person's life is limited by epilepsy. Visit us on Facebook, Twitter, and Instagram.

Evidence That Challenges The Somatic Mutation Theory Of Cancer Dr. Thomas Seyfried, • Contact: thomas.seyfried@bc.edu • Book – Cancer as a Metabolic Disease #ThomasSeyfried#Cancer #MetabolicDisease Dr. Thomas Seyfried, is a professor and author publishing a groundbreaking book; Cancer as a Metabolic Disease: On the Origin, Management, and Prevention of Cancer.This book addresses controversies related to the origins of cancer and provides solutions to cancer management and prevention. It expands upon Otto Warburg's well-known theory that all cancer is a disease of energy metabolism.  However, Warburg did not link his theory to the "hallmarks of cancer" and thus his theory was discredited.  This book aims to provide evidence, through case studies, that cancer is primarily a metabolic disease requiring metabolic solutions for its management and prevention.  Support for this position is derived from critical assessment of current cancer theories.  Brain cancer case studies are presented as a proof of principle for metabolic solutions to disease management, but similarities are drawn to other types of cancer, including breast and colon, due to the same cellular mutations that they demonstrate. The book also provides extensive information showing that cancer can be best defined as a mitochondrial metabolic disease rather than as a genetic disease. This new concept has implications for the development of new non-toxic cancer therapies including the ketogenic diet. Experts in the cancer research field have praised this comprehensive study as one of science's hottest topics. Dr. Thomas Seyfried received his Ph.D. in Genetics and Biochemistry from the University of Illinois, Urbana. He did his undergraduate work at the University of New England, where he recently received the distinguished Alumni Achievement Award. He has a Master's degree in Genetics from Illinois State University.  Thomas Seyfried served with distinction in the United States Army's during the Vietnam War and received numerous medals and commendations. He was a Postdoctoral Fellow in the Department of Neurology at the Yale University School of Medicine and then served on the faculty as an Assistant Professor in Neurology. Other awards and honors have come from such diverse organizations as the American Oil Chemists Society, the National Institutes of Health, The American Society for Neurochemistry, and the Ketogenic Diet Special Interest Group of the American Epilepsy Society.  Dr. Seyfried previously served as Chair, Scientific Advisory Committee for the National Tay-Sachs and Allied Diseases Association and presently serves on several editorial boards, including those for Nutrition & Metabolism, Neurochemical Research, the Journal of Lipid Research, and ASN Neuro, where he is a Senior Editor.  Dr. Seyfried has over 150 peer-reviewed publications and is the author of the book “Cancer as a Metabolic Disease: On the Origin, Management, and Prevention of Cancer (Wiley Press).” To Contact Dr Thomas N. Seyfried, Ph.D. email:  thomas.seyfried@bc.edu Disclaimer:Medical and Health information changes constantly. Therefore, the information provided in this podcast should not be considered current, complete, or exhaustive. Reliance on any information provided in this podcast is solely at your own risk. The Real Truth About Health does not recommend or endorse any specific tests, products, procedures, or opinions referenced in the following podcasts, nor does it exercise any authority or editorial control over that material. The Real Truth About Health provides a forum for discussion of public health issues. The views and opinions of our panelists do not necessarily reflect those of The Real Truth About Health and are provided by those panelists in their individual capacities. The Real Truth About Health has not reviewed or evaluated those statements or claims. 

Are you ready to get intentional with your money, mindset, and marketing? Well, I can't wait to introduce you to some of my best friends in business, Ellen, Renee, Tiffany, and Elise.As we step into 2023, we thought it would be fun to co-host a 2-hour workshop on January 12th, and today, we're giving you a sneak peek. Whether you are a CEO, a founder, a business creative, or a nonprofit marketer, this is designed for ALL of you. And shocker? The price point is $23!If you're ready to get in on all of this amazing goodness, be sure to tune in and click here to sign up for the workshop.Episode Partner: This episode is presented by Feathr. Feathr is trusted by nonprofits of all shapes and wing-spans — from the Humane Society and Meals on Wheels to IJM and the American Epilepsy Society, plus over a thousand more! Don't rely on magic to hit your goals next year. Use Feathr to elevate your digital marketing campaigns and grow impact in 2023. Join me and Noah Barnett on January 26th for a free webinar, all about creating effective re-engagement campaigns. Click here to register.In This Episode:Renee explains how our “upper limit” can self-sabotage and negatively impact our ultimate career success, wealth, and happiness.Elise reveals the three things that often prevent people from achieving their goals (plus, if you join the workshop, you'll get the exact visioning and goal-setting strategy she used to leave her job at Google, buy a house, and grow her multi-six-figure business).Tiffany shares about her secret formulas (typically reserved for her top-paying clients) that will transform your approach to pricing.Ellen tells us about the impact of building her business in public through sharing quarterly income reports.I share the top two social media platforms I'm focusing on in 2023, and why I changed my thinking around feeling like I needed to be on EVERY platform.Resources & LinksJoin me and my personal mastermind group on January 12th for a 2 hour workshop: Let's Get Intentional. With (5) 20-minute personalized workshops, you'll walk away with a 2023 mantra, a visioning workbook, clarity on your offerings, an understanding of your business numbers, and a social media plan uniquely crafted for you. Sign up here for only $23!Connect with Renee Bowen, Elise Armitage, Ellen Yin, and Tiffany Napper and we can't wait to meet you at the workshop!Want to make Missions to Movements even better? Take a screenshot of this episode and share it on Instagram. Be sure to tag @positivequation so I can connect with you. 

Mitochondrial Respiratory Damage Is The Origin Of Cancer Dr. Thomas Seyfried, • Contact: thomas.seyfried@bc.edu • Book – Cancer as a Metabolic Disease #ThomasSeyfried#Cancer #MetabolicDisease Dr. Thomas Seyfried, is a professor and author publishing a groundbreaking book; Cancer as a Metabolic Disease: On the Origin, Management, and Prevention of Cancer.This book addresses controversies related to the origins of cancer and provides solutions to cancer management and prevention. It expands upon Otto Warburg's well-known theory that all cancer is a disease of energy metabolism.  However, Warburg did not link his theory to the "hallmarks of cancer" and thus his theory was discredited.  This book aims to provide evidence, through case studies, that cancer is primarily a metabolic disease requiring metabolic solutions for its management and prevention.  Support for this position is derived from critical assessment of current cancer theories.  Brain cancer case studies are presented as a proof of principle for metabolic solutions to disease management, but similarities are drawn to other types of cancer, including breast and colon, due to the same cellular mutations that they demonstrate. The book also provides extensive information showing that cancer can be best defined as a mitochondrial metabolic disease rather than as a genetic disease. This new concept has implications for the development of new non-toxic cancer therapies including the ketogenic diet. Experts in the cancer research field have praised this comprehensive study as one of science's hottest topics. Dr. Thomas Seyfried received his Ph.D. in Genetics and Biochemistry from the University of Illinois, Urbana. He did his undergraduate work at the University of New England, where he recently received the distinguished Alumni Achievement Award. He has a Master's degree in Genetics from Illinois State University.  Thomas Seyfried served with distinction in the United States Army's during the Vietnam War and received numerous medals and commendations. He was a Postdoctoral Fellow in the Department of Neurology at the Yale University School of Medicine and then served on the faculty as an Assistant Professor in Neurology. Other awards and honors have come from such diverse organizations as the American Oil Chemists Society, the National Institutes of Health, The American Society for Neurochemistry, and the Ketogenic Diet Special Interest Group of the American Epilepsy Society.  Dr. Seyfried previously served as Chair, Scientific Advisory Committee for the National Tay-Sachs and Allied Diseases Association and presently serves on several editorial boards, including those for Nutrition & Metabolism, Neurochemical Research, the Journal of Lipid Research, and ASN Neuro, where he is a Senior Editor.  Dr. Seyfried has over 150 peer-reviewed publications and is the author of the book “Cancer as a Metabolic Disease: On the Origin, Management, and Prevention of Cancer (Wiley Press).” To Contact Dr Thomas N. Seyfried, Ph.D. email:  thomas.seyfried@bc.edu Disclaimer:Medical and Health information changes constantly. Therefore, the information provided in this podcast should not be considered current, complete, or exhaustive. Reliance on any information provided in this podcast is solely at your own risk. The Real Truth About Health does not recommend or endorse any specific tests, products, procedures, or opinions referenced in the following podcasts, nor does it exercise any authority or editorial control over that material. The Real Truth About Health provides a forum for discussion of public health issues. The views and opinions of our panelists do not necessarily reflect those of The Real Truth About Health and are provided by those panelists in their individual capacities. The Real Truth About Health has not reviewed or evaluated those statements or claims. 

Check out our new Patreon page! Get access to the Boundless Body Radio Premium Podcast, with a new episode added every other week! Other perks include early releases of our episodes, extended video content, and group and one on one coaching!Let the title of this episode sink in as you listen to this one.Dr. Thomas Seyfried is a returning guest on our show! Be sure to check out his first appearance on Boundless Body Radio on episode 60, which one of the most fascinating discussions we've ever had, all about cancer as a metabolic disease! Thomas N. Seyfried received his Ph.D. in Genetics and Biochemistry from the University of Illinois, Urbana, in 1976. He was a Postdoctoral Fellow in the Department of Neurology at the Yale University School of Medicine and then served on the faculty as an Assistant Professor in Neurology. Other awards and honors have come from such diverse organizations as the American Oil Chemists Society, the National Institutes of Health, The American Society for Neurochemistry, the Ketogenic Diet Special Interest Group of the American Epilepsy Society, the Academy of Comprehensive and Complementary Medicine, and the American College of Nutrition. Dr. Seyfried has over 150 peer-reviewed publications and is the author of the book, Cancer as a Metabolic Disease: On the Origin, Management, and Prevention of Cancer (Wiley, 1st ed., 2012).Find Dr. Seyfried at-https://foundationformetaboliccancertherapies.com/Movie, coming soon- CANCERREVOLUTION: A Cancer Science Documentary with Dr. Seyfried and former podcast guest Travis Christofferson.Find Boundless Body at-myboundlessbody.comBook a session with us here! Find Boundless Body at- myboundlessbody.com Book a session with us here! Check out our new Patreon page!

New 2022 - Cancer As A Metabolic Disease: Implications For Novel Therapeutics - Thomas N. Seyfried, PhD Dr. Thomas Seyfried, • Contact: thomas.seyfried@bc.edu • Book – Cancer as a Metabolic Disease #ThomasSeyfried#Cancer #MetabolicDisease Dr. Thomas Seyfried, is a professor and author publishing a groundbreaking book; Cancer as a Metabolic Disease: On the Origin, Management, and Prevention of Cancer.This book addresses controversies related to the origins of cancer and provides solutions to cancer management and prevention. It expands upon Otto Warburg's well-known theory that all cancer is a disease of energy metabolism.  However, Warburg did not link his theory to the "hallmarks of cancer" and thus his theory was discredited. This book aims to provide evidence, through case studies, that cancer is primarily a metabolic disease requiring metabolic solutions for its management and prevention.  Support for this position is derived from critical assessment of current cancer theories.  Brain cancer case studies are presented as a proof of principle for metabolic solutions to disease management, but similarities are drawn to other types of cancer, including breast and colon, due to the same cellular mutations that they demonstrate.The book also provides extensive information showing that cancer can be best defined as a mitochondrial metabolic disease rather than as a genetic disease. This new concept has implications for the development of new non-toxic cancer therapies including the ketogenic diet. Experts in the cancer research field have praised this comprehensive study as one of science's hottest topics. Dr. Thomas Seyfried received his Ph.D. in Genetics and Biochemistry from the University of Illinois, Urbana. He did his undergraduate work at the University of New England, where he recently received the distinguished Alumni Achievement Award. He has a Master's degree in Genetics from Illinois State University. Thomas Seyfried served with distinction in the United States Army's during the Vietnam War and received numerous medals and commendations. He was a Postdoctoral Fellow in the Department of Neurology at the Yale University School of Medicine and then served on the faculty as an Assistant Professor in Neurology. Other awards and honors have come from such diverse organizations as the American Oil Chemists Society, the National Institutes of Health, The American Society for Neurochemistry, and the Ketogenic Diet Special Interest Group of the American Epilepsy Society. Dr. Seyfried previously served as Chair, Scientific Advisory Committee for the National Tay-Sachs and Allied Diseases Association and presently serves on several editorial boards, including those for Nutrition & Metabolism, Neurochemical Research, the Journal of Lipid Research, and ASN Neuro, where he is a Senior Editor. Dr. Seyfried has over 150 peer-reviewed publications and is the author of the book “Cancer as a Metabolic Disease: On the Origin, Management, and Prevention of Cancer (Wiley Press).”To Contact Dr Thomas N. Seyfried, Ph.D. email:  thomas.seyfried@bc.edu CLICK HERE - To Checkout Our MEMBERSHIP CLUB: http://www.realtruthtalks.com  • Social Media ChannelsFacebook: https://www.facebook.com/TRTAHConferenceInstagram : https://www.instagram.com/therealtruthabouthealth/ Twitter: https://twitter.com/RTAHealth Linkedin: https://www.linkedin.com/company/the-real-truth-about-health-conference/ Youtube: https://www.youtube.com/c/TheRealTruthAboutHealth    • Check out our Podcasts  Visit us on Apple Podcast and Itunes search:  The Real Truth About Health Free 17 Day Live Online Conference Podcast Amazon: https://music.amazon.com/podcasts/23a037be-99dd-4099-b9e0-1cad50774b5a/real-truth-about-health-live-online-conference-podcastSpotify: https://open.spotify.com/show/0RZbS2BafJIEzHYyThm83J Google:https://www.google.com/podcasts?feed=aHR0cHM6Ly9mZWVkcy5zaW1wbGVjYXN0LmNvbS8yM0ZqRWNTMg%3D%3DStitcher: https://www.stitcher.com/podcast/real-truth-about-health-live-online-conference-podcastAudacy: https://go.audacy.com/partner-podcast-listen-real-truth-about-health-live-online-conference-podcastiHeartRadio: https://www.iheart.com/podcast/269-real-truth-about-health-li-85932821/ Deezer: https://www.deezer.com/us/show/2867272 Reason: https://reason.fm/podcast/real-truth-about-health-live-online-conference-podcast • Other Video ChannelsYoutube:https://www.youtube.com/c/TheRealTruthAboutHealthVimeo:https://vimeo.com/channels/1733189Rumble:  https://rumble.com/c/c-1111513 Facebook:https://www.facebook.com/TRTAHConference/videos/?ref=page_internal DailyMotion: https://www.dailymotion.com/TheRealTruthAboutHealth BitChute:  https://www.bitchute.com/channel/JQryXTPDOMih/ Disclaimer:Medical and Health information changes constantly. Therefore, the information provided in this podcast should not be considered current, complete, or exhaustive. Reliance on any information provided in this podcast is solely at your own risk. The Real Truth About Health does not recommend or endorse any specific tests, products, procedures, or opinions referenced in the following podcasts, nor does it exercise any authority or editorial control over that material. The Real Truth About Health provides a forum for discussion of public health issues. The views and opinions of our panelists do not necessarily reflect those of The Real Truth About Health and are provided by those panelists in their individual capacities. The Real Truth About Health has not reviewed or evaluated those statements or claims. 

Get access to higher-level medical knowledge as Dr. Omar Danoun shares his insights on epilepsy and post-Covid neurological disorders to help you understand and treat them efficiently. So tune in!IN THIS EPISODE YOU WILL LEARN:American vs. Palestinian medical systemsWhy it's better to explain medical terms to patients in a simple mannerEpilepsy: Diagnosis, symptoms, and treatmentsCovid19-related neurological complications and how to treat themPost-Covid brain fog vs. memory disordersWhat is Parosmia and how is it treatedRESOURCES/LINKS MENTIONED:NEW Laser treatment for Epilepsy and Seizures, LITT: https://www.youtube.com/watch?v=wjOp-IuIZ-gCognitive Therapy: https://www.eehealth.org/services/rehabilitation/specialties/cognitive-therapy/ABOUT: DR. OMAR DANOUNDr. Omar Danoun is a leading expert on epilepsy and neurology. He has worked with multiple epilepsy and neurology societies and organizations, like the Epilepsy Foundation and the American Epilepsy Society, to raise awareness for epilepsy and related conditions. His insights are widely regarded by people with epilepsy and their families.CONNECT WITH: DR. OMARWebsite: Dr. Omar Danoun: https://www.dromardanoun.com/YouTube: Dr. Omar Danoun: https://www.youtube.com/channel/UCUpOvIIWABhYKqxrls-vcVgInstagram: @dromardanoun: https://www.instagram.com/dromardanoun/TikTok: @dromardanoun: https://www.tiktok.com/@dromardanounTwitter: @omar_danoun: https://twitter.com/omar_danounFacebook: Dr. Omar Danoun د. عمر دنون: https://www.facebook.com/DanounNeurologyCONNECT WITH US:Website: http://www.hammersnhugs.comYouTube: https://www.youtube.com/c/AhnaFulmerHammersNHugsInstagram: https://www.instagram.com/ahna_hammersnhugs/]Facebook: https://www.facebook.com/hammersnhugs

Professor Thomas Seyfried has published over 150 peer reviewed studies in biology and cancer biology and has verified Nobel Prize Winner Otto Warburg's assertation that cancer is a metabolic disease of the mitochondria, not a genetic disorder. If we misunderstand the origin of the disease, the treatment is going to be wrong as well, and this is exactly what has happened. Ever think about why the cancer rates have tripled in the past 40 years? Well, this is why. Thomas N. Seyfried received his Ph.D. in Genetics and Biochemistry from the University of Illinois, Urbana, in 1976. He did his undergraduate work at the University of New England, where he recently received the distinguished Alumni Achievement Award. He also holds a Master's degree in Genetics from Illinois State University. Thomas Seyfried served with distinction in the United States Army's First Cavalry Division during the Vietnam War and received numerous medals and commendations. He was a Postdoctoral Fellow in the Department of Neurology at the Yale University School of Medicine and then served on the faculty as an Assistant Professor in Neurology. Other awards and honors have come from such diverse organizations as the American Oil Chemists Society, the National Institutes of Health, The American Society for Neurochemistry, the Ketogenic Diet Special Interest Group of the American Epilepsy Society, the Academy of Comprehensive and Complementary Medicine, and the American College of Nutrition. Dr. Seyfried previously served as Chair, Scientific Advisory Committee for the National Tay-Sachs and Allied Diseases Association and presently serves on several editorial boards, including those for Nutrition & Metabolism, Neurochemical Research, the Journal of Lipid Research, and ASN Neuro, where he is a Senior Editor. Dr. Seyfried is also the author of the book, Cancer as a Metabolic Disease: On the Origin, Management, and Prevention of Cancer (Wiley, 1st ed., 2012).   FOLLOW PROFESSOR SEYFRIED: Instagram: https://www.instagram.com/thomasseyfriedbc/   FOLLOW AND CONTACT ME AT: MY PATREON https://www.patreon.com/AnthonyChaffeeMD Sign up for our 30-day carnivore challenge and group here! https://www.howtocarnivore.com/ ORDER THE CARNIVORE BAR! Discount Code "Anthony" for 10% off all orders! https://the-carnivore-bar.myshopify.com/?sca_ref=1743809.v3IrTuyDIi ORDER CARNIVORE CRISPS! Discount Code "DRCHAFFEEMD" for 10% off all orders! www.carnivorecrisps.com For Consults or collaborations, please email me at: AnthonyChaffee@gmail.com Shop Amazon https://www.amazon.com/shop/anthonychaffeemd?ref=ac_inf_hm_vp INSTAGRAM: @anthonychaffeemd www.instagram.com/anthonychaffeemd/ TWITTER: @Anthony_Chaffee TIKTOK: @AnthonyChaffeeMD Facebook Group: The Carnivore Fix https://www.facebook.com/groups/1078241659422805 Weekly Q&A sessions: https://www.patreon.com/thecarnivorelife For more of my interviews and discussions, as well as other resources, go to my Linktree at: https://linktr.ee/DrChaffeeMD OR my website at: www.TheCarnivoreLife.com And please like, comment, share, and subscribe to my podcast here and Apple/Google/Spotify podcasts, as well as my YouTube Channel to get updates on all new content, and please give a 5-star rating! Music track: Acoustic Breeze from Bensound.com   RESOURCES: Professor Thomas Seyfried cancer as a metabolic disease https://youtu.be/06e-PwhmSq8 Ketogenic diets and cancer treatment https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6375425/ Cancer Treatment With the Ketogenic Diet: A Systematic Review and Meta-analysis of Animal Studies https://www.frontiersin.org/articles/10.3389/fnut.2021.594408/full Carnivore cancer treatment center, Hungary https://humanperformanceoutliers.libsyn.com/episode-84-dr-zsofia-clemens Keto as cancer treatment and prevention https://youtu.be/DlI6DMZxgBY Dr Thomas Seyfried Cancer, mitochondria, and ketogenic diet and fasting in cancer treatment https://youtu.be/PuG5XZSR4vs Keto and glutamine, GBM treatment Seyfried https://www.nature.com/articles/s42003-019-0455-x Cancer causing polyunsaturated fat (Mitochondria effect) https://www.sciencedirect.com/science/article/pii/S2213231714001359 Red meat doesn't increase risk of colon cancer or all cause mortality https://www.mdpi.com/2072-6643/13/1/32   #carnivore #keto #weightloss #thecarnivorelife #carnivorediet #weightsandsteaks #teamcarnivore #meatheals #yestomeat #nutrition #diet #autoimmune #rugby #rugbyunion #rugbyplayer #weightlossjourney #weightlifting #steak #bodybuilding #strength #strengthtraining #weighttraining #zerocarb #ketovore #ribeye #liondiet #ketodiet #carnivoreketo #ketotransformation #carnivore75hard #vegan #sowell #thomassowell #dairy #milk #cheese #nsng #lchf #lcif

How do staff vaccination rates impact COVID-19 outcomes in nursing homes? Find out about this and more in today's PV Roundup podcast.

Thomas N. Seyfried received his Ph.D. in Genetics and Biochemistry from the University of Illinois, Urbana, in 1976. He did his undergraduate work at the University of New England, where he recently received the distinguished Alumni Achievement Award. He also holds a Master's degree in Genetics from Illinois State University. Thomas Seyfried served with distinction in the United States Army's First Cavalry Division during the Vietnam War and received numerous medals and commendations. He was a Postdoctoral Fellow in the Department of Neurology at the Yale University School of Medicine and then served on the faculty as an Assistant Professor in Neurology. Other awards and honours have come from such diverse organisations as the American Oil Chemists Society, the National Institutes of Health, The American Society for Neurochemistry, the Ketogenic Diet Special Interest Group of the American Epilepsy Society, the Academy of Comprehensive and Complementary Medicine, and the American College of Nutrition. Dr. Seyfried previously served as Chair, Scientific Advisory Committee for the National Tay-Sachs and Allied Diseases Association and presently serves on several editorial boards, including those for Nutrition & Metabolism, Neurochemical Research, the Journal of Lipid Research, and ASN Neuro, where he is a Senior Editor. Dr. Seyfried has over 150 peer-reviewed publications and is the author of the book, Cancer as a Metabolic Disease: On the Origin, Management, and Prevention of Cancer (Wiley, 1st ed., 2012). Find him on Twitter: https://twitter.com/tnseyfried or YouTube:https://www.youtube.com/channel/UC3usB3s0qqOo4wImv3fgf5A/featured This episode is hosted by Dr. Shawn Baker MD. Find him at https://shawn-baker.com Donate to the Carnivore Diet Clinical Trial: https://gofundme.com/f/carnivore-research

Thank you for tuning into Life's Best Medicine. Brandy Parker-McFadden is a wife, mother, patient advocate, Executive Director/Founder of My Epilepsy Story and a woman living with epilepsy.  She is a member of the American Epilepsy Society and American Epilepsy Society Epilepsy Leadership Counsil (ELC). Mrs. McFadden is a member of the AES ELC: Surveillance/Prevention Working Group and Membership Committee, a Consultant and Patient Advocate on the MONEAD Project, and COPE. Mrs. McFadden was named PCORI Ambassador in 2014 and still continues to this day. In addition, she is also a member of the American Academy of Neurology: Epilepsy Quality Measure Development Work Group and American Academy of Neurology: Women with Epilepsy Guideline Work Group. Mrs. McFadden's passion is to advocate for patient-centered care as well as patient-centered research. She believes the patient voice needs for be heard by allowing patients to have a seat at the table when decisions are being made regarding healthcare and when doing research. She believes that we can “bridge the gap” for females by addressing women's health issues across the globe in the clinical and research settings. Also, she believes that women's health issues are generally “just discussed” on a global scale but never fully addressed with plans being implemented to improve the patient outcomes of the female population.  Mrs. McFadden is also passionate about having a national pregnancy registry that is solely federally funded. In addition, she believes in “Women Demand Change”, with men standing with them, to make healthcare as an institution better for them and the next generation of females.  Life's Best Medicine According to Brandy: “Faith—Faith in God and faith that there is a bigger picture and purpose for the hardships you encounter.” For more information, please see the links below. Thank you for listening!   Links:   Brandy McFadden: Twitter My Epilepsy Story Instagram Facebook   Dr. Brian Lenzkes:  Website

At least 3.4+ Million Live with Epilepsy in the U.S.2National Neurology Expert Offers Immediate Steps to Mitigate Deadly Risks, ReduceRelated Healthcare Costs and BurdenGUEST:  Dr. James Wheless, Professor and Chief of Pediatric Neurology, Le Bonheur Chair in Pediatric Neurology, University of Tennessee Health Science CenterBackground:Epilepsy is a disorder of the brain that is characterized by seizures.3 Seizures can be debilitating and even life threatening.4 Just one convulsive seizure is a potentially shattering event that increases the risk of significant health consequences, including physical injury and cognitive decline.5,6,7 Although epilepsy is widely recognized, few understand it – even those who know someone with the disorder.1 And this misunderstanding causes a stigma that makes it harder to treat,1 while the number of adults and children challenged by epilepsy in the U.S. is increasing.2Freedom from seizures is the ultimate goal in epilepsy treatment.8 Yet missed doses are a common occurrence that can get in the way of achieving it. For most people with this condition, it's a question of when, not if they will miss a dose of their medication. In fact, 71% of epilepsy patients surveyed have missed at least 1 dose.9 And, almost 50% report that a missed dose of medication was followed by a subsequent seizure.9 Poor seizure control means a higher likelihood of emergency room visits and greater healthcare costs.10 Yet many with epilepsy may be reluctant to discuss their struggles even with their doctor.11Dr. James Wheless, Professor and Chief of Pediatric Neurology, Le Bonheur Chair in Pediatric Neurology, University of Tennessee Health Science Center will help educate your viewers about epilepsy, including the crucial role of individual lifestyle in treatment, and advances in epilepsy management that will help people living with epilepsy achieve seizure freedom.More information can be found at www.epilapsey.comMore About Dr. James WhelessDr. Wheless is Professor and Chief of Pediatric Neurology and the Le Bonheur Chair in Pediatric Neurology at the University of Tennessee Health Science Center in Memphis. He also serves as Director of the Neuroscience Institute and the Le Bonheur Comprehensive Epilepsy Program for the Le Bonheur Children's Hospital.Dr. Wheless is a paid consultant on behalf of Eisai Inc.REFERENCEHerrmann LK, et al. Epilepsy misconceptions and stigma reduction: Current status in Western Countries. Epilepsy Behav. 2016;60:165-173.Zack MM, Kobau R. National and State Estimates of the Numbers of Adults and Children with Active Epilepsy — the United States, 2015. MMWR Morb Mortal Wkly Rep. 2017;66:821–825.Institute of Medicine Committee on the Public Health Dimensions of the Epilepsies. Summary.  Epilepsy Across the Spectrum: Promoting Health and Understanding. England MJ, Liverman CT, Schultz AM, Strawbridge LM, editors. Washington, DC: National Academies Press; 2012.Harden C, et al. Practice Guideline Summary: Sudden Unexpected Death in Epilepsy Incidence Rates and Risk Factors:  Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Epilepsy Currents. 2015;17(3):180-187.Friedman DE, et al. Recurrent seizure-related injuries in people with epilepsy at a tertiary epilepsy center: A 2-year longitudinal study. Epilepsy Behav. 2010;19(3):400-404.Thompson PJ, Duncan JS. Cognitive decline in severe epilepsy. Epilepsia. 2005;45(11):1780-1787.Berg AT, et al. Mortality risks in new-onset childhood epilepsy. Pediatrics. 2013;132(1):124-131St. Louis, EK. Minimizing AED Adverse Effects: Improving Quality of Life in the Interictal State in Epilepsy Care. Current Neuropharmacol. 2009;7:106-114.Cramer JA, Glassman M, Rienzi V. The relationship between poor medication compliance and seizures. Epilepsy Behav. 2002;3:338-342.Divino V, Petrilla AA, Bollu V, et al. Clinical and economic burden of breakthrough seizures. Epilepsy Behav. 2015;51:40-47.Buelow J, Miller W, Fishman J. Development of an Epilepsy Nursing Communication Tool: Improving the Quality of Interactions Between Nurses and Patients with Seizures. Jour of Neurosci Nurs. 2018;50(2):74-80.

At least 3.4+ Million Live with Epilepsy in the U.S.2National Neurology Expert Offers Immediate Steps to Mitigate Deadly Risks, ReduceRelated Healthcare Costs and BurdenGUEST:  Dr. James Wheless, Professor and Chief of Pediatric Neurology, Le Bonheur Chair in Pediatric Neurology, University of Tennessee Health Science CenterBackground:Epilepsy is a disorder of the brain that is characterized by seizures.3 Seizures can be debilitating and even life threatening.4 Just one convulsive seizure is a potentially shattering event that increases the risk of significant health consequences, including physical injury and cognitive decline.5,6,7 Although epilepsy is widely recognized, few understand it – even those who know someone with the disorder.1 And this misunderstanding causes a stigma that makes it harder to treat,1 while the number of adults and children challenged by epilepsy in the U.S. is increasing.2Freedom from seizures is the ultimate goal in epilepsy treatment.8 Yet missed doses are a common occurrence that can get in the way of achieving it. For most people with this condition, it's a question of when, not if they will miss a dose of their medication. In fact, 71% of epilepsy patients surveyed have missed at least 1 dose.9 And, almost 50% report that a missed dose of medication was followed by a subsequent seizure.9 Poor seizure control means a higher likelihood of emergency room visits and greater healthcare costs.10 Yet many with epilepsy may be reluctant to discuss their struggles even with their doctor.11Dr. James Wheless, Professor and Chief of Pediatric Neurology, Le Bonheur Chair in Pediatric Neurology, University of Tennessee Health Science Center will help educate your viewers about epilepsy, including the crucial role of individual lifestyle in treatment, and advances in epilepsy management that will help people living with epilepsy achieve seizure freedom.More information can be found at www.epilapsey.comMore About Dr. James WhelessDr. Wheless is Professor and Chief of Pediatric Neurology and the Le Bonheur Chair in Pediatric Neurology at the University of Tennessee Health Science Center in Memphis. He also serves as Director of the Neuroscience Institute and the Le Bonheur Comprehensive Epilepsy Program for the Le Bonheur Children's Hospital.Dr. Wheless is a paid consultant on behalf of Eisai Inc.REFERENCEHerrmann LK, et al. Epilepsy misconceptions and stigma reduction: Current status in Western Countries. Epilepsy Behav. 2016;60:165-173.Zack MM, Kobau R. National and State Estimates of the Numbers of Adults and Children with Active Epilepsy — the United States, 2015. MMWR Morb Mortal Wkly Rep. 2017;66:821–825.Institute of Medicine Committee on the Public Health Dimensions of the Epilepsies. Summary.  Epilepsy Across the Spectrum: Promoting Health and Understanding. England MJ, Liverman CT, Schultz AM, Strawbridge LM, editors. Washington, DC: National Academies Press; 2012.Harden C, et al. Practice Guideline Summary: Sudden Unexpected Death in Epilepsy Incidence Rates and Risk Factors:  Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Epilepsy Currents. 2015;17(3):180-187.Friedman DE, et al. Recurrent seizure-related injuries in people with epilepsy at a tertiary epilepsy center: A 2-year longitudinal study. Epilepsy Behav. 2010;19(3):400-404.Thompson PJ, Duncan JS. Cognitive decline in severe epilepsy. Epilepsia. 2005;45(11):1780-1787.Berg AT, et al. Mortality risks in new-onset childhood epilepsy. Pediatrics. 2013;132(1):124-131St. Louis, EK. Minimizing AED Adverse Effects: Improving Quality of Life in the Interictal State in Epilepsy Care. Current Neuropharmacol. 2009;7:106-114.Cramer JA, Glassman M, Rienzi V. The relationship between poor medication compliance and seizures. Epilepsy Behav. 2002;3:338-342.Divino V, Petrilla AA, Bollu V, et al. Clinical and economic burden of breakthrough seizures. Epilepsy Behav. 2015;51:40-47.Buelow J, Miller W, Fishman J. Development of an Epilepsy Nursing Communication Tool: Improving the Quality of Interactions Between Nurses and Patients with Seizures. Jour of Neurosci Nurs. 2018;50(2):74-80.

In today's episode, we're talking with Dr. Shawna Strickland as she shares her career journey with the AARC and now beyond as she transitions to the American Epilepsy Society.

As many as 1% of the world has epilepsy, but far more than will have a seizure in their lifetime. Not everyone needs a seizure medication, some people are even harmed by them. So who warrants treatment, and what do you start with. Consider today’s program an intro to AED decision making. For educational purposes only, of course. Not to guide any healthcare provider’s decision making. Produced by James E. Siegler. Music courtesy of Lee Rosevere, Cellophane Sam, Jon Watts, Josh Woodward, and Rafael Archangel. The opening theme was composed by Jimothy Dalton. Sound effects by Mike Koenig and Daniel Simion. Unless otherwise mentioned in the podcast, no competing financial interests exist in the content of this episode. BrainWaves' podcasts and online content are intended for medical education only and should not be used for clinical decision making. Be sure to follow us on Twitter @brainwavesaudio for the latest updates to the podcast. REFERENCES Hauser WA, Rich SS, Annegers JF and Anderson VE. Seizure recurrence after a 1st unprovoked seizure: an extended follow-up. Neurology. 1990;40:1163-70. Randomized clinical trial on the efficacy of antiepileptic drugs in reducing the risk of relapse after a first unprovoked tonic-clonic seizure. First Seizure Trial Group (FIR.S.T. Group). Neurology. 1993;43:478-83. Hui AC, Tang A, Wong KS, Mok V and Kay R. Recurrence after a first untreated seizure in the Hong Kong Chinese population. Epilepsia. 2001;42:94-7. Koepp MJ and Woermann FG. Imaging structure and function in refractory focal epilepsy. The Lancet Neurology. 2005;4:42-53. Marson A, Jacoby A, Johnson A, Kim L, Gamble C, Chadwick D and Medical Research Council MSG. Immediate versus deferred antiepileptic drug treatment for early epilepsy and single seizures: a randomised controlled trial. Lancet. 2005;365:2007-13. Manjunath R, Davis KL, Candrilli SD and Ettinger AB. Association of antiepileptic drug nonadherence with risk of seizures in adults with epilepsy. Epilepsy Behav. 2009;14:372-8. Fountain NB. Choosing among antiepileptic drugs. Continuum (Minneap Minn). 2010;16:121-35. Fisher RS, Acevedo C, Arzimanoglou A, Bogacz A, Cross JH, Elger CE, Engel J, Jr., Forsgren L, French JA, Glynn M, Hesdorffer DC, Lee BI, Mathern GW, Moshe SL, Perucca E, Scheffer IE, Tomson T, Watanabe M and Wiebe S. ILAE official report: a practical clinical definition of epilepsy. Epilepsia. 2014;55:475-82. Krumholz A, Wiebe S, Gronseth GS, Gloss DS, Sanchez AM, Kabir AA, Liferidge AT, Martello JP, Kanner AM, Shinnar S, Hopp JL and French JA. Evidence-based guideline: Management of an unprovoked first seizure in adults: Report of the Guideline Development Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology. 2015;84:1705-13. Bouma HK, Labos C, Gore GC, Wolfson C and Keezer MR. The diagnostic accuracy of routine electroencephalography after a first unprovoked seizure. European journal of neurology : the official journal of the European Federation of Neurological Societies. 2016;23:455-63. Leone MA, Giussani G, Nolan SJ, Marson AG and Beghi E. Immediate antiepileptic drug treatment, versus placebo, deferred, or no treatment for first unprovoked seizure. The Cochrane database of systematic reviews. 2016:CD007144.

Vitals & Useful Links: Learn about management of a first time seizure (see spoilers below if you want to find out how) EM Clerkship Podcast - Seizure (spoilers) EM Clerkship Podcast - Status Epilepticus ACEP Clinical Policies - Seizure EMJC is back to our regularly scheduled episodes! This week Arman (MS4) leads Kyle (MS4) and Frankie (MS4) through a case of a woman presenting after a first time seizure. How would you approach this case? As always, we learn some important management strategies for seizures. If you have any questions, concerns, or comments, please email us at emjccast@gmail.com *****EPISODE SPOILERS BELOW***** Here's Arman's Article on Management of Status Epilepticus Glauser, T., Shinnar, S., Gloss, D., Alldredge, B., Arya, R., Bainbridge, J., Bare, M., Bleck, T., Dodson, W. E., Garrity, L., Jagoda, A., Lowenstein, D., Pellock, J., Riviello, J., Sloan, E., & Treiman, D. M. (2016). Evidence-Based Guideline: Treatment of Convulsive Status Epilepticus in Children and Adults: Report of the Guideline Committee of the American Epilepsy Society. Epilepsy currents, 16(1), 48–61. https://doi.org/10.5698/1535-7597-16.1.48 Arman's Article on the ESETT Trial Cock, H. R., & ESETT Group. (2011). Established status epilepticus treatment trial (ESETT). Epilepsia, 52, 50-52. EM Cases - Management of Status Epilepticus DISCLAIMER: The views/opinions expressed in this podcast are that of the hosts/guests and do not reflect their respective institutions. This is NOT a medical advice podcast, if you are having a medical emergency you should call 911 and get help. This is an educational podcast, and as such, sometimes we get things wrong - if you notice this, please email us at emjccast@gmail.com.

Dr. Rodrigo Quian Quiroga is a Professor and Director of the Centre for Systems Neuroscience at the University of Leicester in the United Kingdom. He is also an author of the books Borges and Memory, Principles of Neural Coding, Imaging Brain Function with EEG, and The Forgetting Machine. Rodrigo is interested in understanding how memory works and how the brain works in general. He conducts experiments to determine how the neurons in our brain make us see, feel, make decisions, and remember the things we experience and learn in our lives. The memory research in Rodrigo’s lab investigates how memories are formed, stored, consolidated, and forgotten. Rodrigo also enjoys getting out of the lab to give his mind a break from thinking about experiments. In particular, he enjoys hanging out with his wife and kids, playing sports, and practicing Judo. Rodrigo received his undergraduate training in physics from the University of Buenos Aires in Argentina and was awarded his PhD in Applied Mathematics from the University of Luebeck in Germany. He was a postdoctoral fellow at the Research Center Juelich in Germany and he received a Sloan Fellowship to conduct research at the California Institute of Technology. Rodrigo also worked briefly at RIKEN in Japan and at the University of Nijmegen in The Netherlands. Rodrigo has received numerous awards and honors including the Royal Society Wolfson Research Merit Award, a Young Investigator Award from the American Epilepsy Society, and Rodrigo was also named one of 10 UK RISE Leaders in Science and Engineering in 2014. Rodrigo spoke with us about his experiences his career, research, and life.

El cerebro está hecho de células, pero para entenderlo hace falta comprender su química y también su electricidad. Neuronas chisporroteantes, dirían algunos. Pues eso es exactamente lo que hacen los expertos en electrofisiología. ¿Cómo puede una neurona producir electricidad? ¿Son las únicas células capaces de hacerlo? ¿Cómo conseguimos medir esas descargas eléctricas? ¿Podemos utilizar ese conocimiento para comunicarnos con nuestro cerebro usando electricidad? Las respuestas son fascinantes, porque abren un mundo de posibilidades y dan a la neurociencia un saber diferente al de otras ciencias de carácter biológico. Hablemos de nuestro cerebro, un cerebro eléctrico.Para ello tenemos con nosotros a Liset Menéndez de la Prida, que es graduada en Física, doctora en Neurociencias. Además, ha sido editora del Journal of Neuroscience, Journal of Neuroscience Methods y eNeuro y ha formado parte de los cargos de American Epilepsy Society, la Sociedad Española de Neurociencias y la Sociedad Española de Epilepsia. Actualmente lidera el Laboratorio de Circuitos Neuronales en el Instituto Cajal en Madrid y, por si fuera poco, a sus publicaciones científicas se suma un libro de divulgación del que es autora: La Neurociencia del Espacio y el Tiempo.

Author: Charlene Gnisci Melton, PharmD Educational Pearls: Status Epilepticus is defined as continuous seizure activity for >5 minutes, or 2 or more seizures without full return to consciousness between events Status epilepticus is a true neurologic emergency with significant morbidity and mortality Aggressive, early treatment of status epilepticus is essential as GABA receptors will regress over time and make benzodiazepines less effective as time elapses Go large with doses of benzodiazepines and repeat doses if necessary: In adults this means lorazepam 4 mg IV push or Midazolam 10 mg intramuscular if no IV access Second line agents include: Levetiracetam (Keppra) 60 mg/kg up to 4500mg Valproic Acid (40 mg/kg up to 3000 mg) Keppra has an arguably better side effect profile and compatibility compared to other second-line agents Third line agents include intubation and sedation with propofol, benzodiazepines, or even ketamine Editor’s note: from a time management perspective, call for your second-line treatment early to get it from pharmacy while you slam the benzodiazepines, then it will be arriving hopefully when you need it, and no harm if you don’t. Oh, and don’t forget a fingerstick glucose. References Glauser T, Shinnar S, Gloss D, et al. Evidence-Based Guideline: Treatment of Convulsive Status Epilepticus in Children and Adults: Report of the Guideline Committee of the American Epilepsy Society. Epilepsy Curr. 2016;16(1):48–61. doi:10.5698/1535-7597-16.1.48 Walker, M.C. Pathophysiology of status epilepticus. Neuroscience Letters. 2018:667:84-91. https://doi.org/10.1016/j.neulet.2016.12.044 Summarized by Jackson Roos, MS3 | Edited by Erik Verzemnieks, MD  

If you’ve ever watched a patient, friend, or family member have a seizure, you know how scary and stressful it can be for everyone involved. It’s even more stressful when you can’t get the seizure to stop - this is called status epilepticus. Usually, benzodiazepines are our first line medication. If benzos don’t work, we all have our favorite second, and even third line agents to try to break seizures. But how well do they really work? Is one better than another? Or safer?  This episode starts with a personal story told by parents of a child who suffers from epilepsy. Then we welcome guest host, Dr. Jason Woods of the Little Big Med podcast, to help us answer these questions. Dr. Jim Chamberlain is the pediatric principal investigator for the ESETT trial, in which he and his colleagues studied three common second line anti epileptic medications. He shares some of the novel statistical methods they used and the results that were recently published in the New England Journal of Medicine. Then we speak with our own Dr. Daniel Nishijima, general EM physician and site Co-PI for the trial, about the implications for adults and how the results have (or have not?) changed his practice.   What are your favorite first and second line medications for status epilepticus? When do you decide to intubate? We’d love to hear how you practice. Connect with us on social media, @empulsepodcast, or at ucdavisem.com.  *** Registration is still open for the 43rd annual UC Davis Emergency Medicine Winter Conference, February 24th-29th at the Ritz Carlton in Lake Tahoe! *** Hosts: Dr. Julia Magaña, Assistant Professor of Pediatric Emergency Medicine at UC Davis Dr. Sarah Medeiros, Assistant Professor of Emergency Medicine at UC Davis Dr. Jason Woods, Assistant Professor of Pediatric Emergency Medicine at Children’s Hospital Colorado, Host of the Little Big Med podcast Guests: Dr. Jim Chamberlain, Professor of Pediatrics and Emergency Medicine at George Washington University and Children’s National Hospital, Pediatric Principal Investigator for the ESETT trial Dr. Daniel Nishijima, Associate Professor of Emergency Medicine at UC Davis, Site Co-Pricipal Investigator for the ESETT trial Resources: SAEM seizure and status epilepticus resources Kapur J, Elm J, Chamberlain J, et al. Randomized Trial of Three Anticonvulsant Medications for Status Epilepticus. N Engl J Med. 2019;381(22):2103-2113. Little Big Med Podcast Glauser T, Shinnar S, Gloss D, et al. Evidence-based guideline: treatment of convulsive status epilepticus in children and adults: report of the Guideline Committee of the American Epilepsy Society. Epilepsy Curr 2016;16: 48–61.  Dalziel SR, Borland ML, Furyk J, et al. Levetiracetam versus phenytoin for second-line treatment of convulsive status epilepticus in children (ConSEPT): an open-label, multicentre, randomised controlled trial. Lancet 2019; published online April 17. Lyttle MD, Rainford NEA, Gamble C, et al. Levetiracetam versus phenytoin for second-line treatment of paediatric convulsive status epilepticus (EcLiPSE): a multicentre, open-label, randomised trial. Lancet 2019; published online April 17. Connor JT, Elm JJ, Broglio KR, ESETT and ADAPT-IT Investigators. Bayesian adaptive trials offer advantages in comparative effectiveness trials: an example in status epilepticus J Clin Epidemiol 2013;  Zaccara G, Giannasi G, Oggioni R, et al. Challenges in the treatment of convulsive status epilepticus. Seizure. 2017;47:17-24.  Ilvento L, Rosati A, Marini C, L’Erario M, Mirabile L, Guerrini R. Ketamine in refractory convulsive status epilepticus in children avoids endotracheal intubation. Epilepsy Behav. 2015;49:343-346.  Niquet J, Baldwin R, Norman K, Suchomelova L, Lumley L, Wasterlain C. Midazolam-ketamine dual therapy stops cholinergic status epilepticus and reduces Morris water maze deficits. Epilepsia. 2016;57(9):1406-1415.  ***

In this episode, we discuss seizures in the ICU. We cover a broad range of topics related to the initial management of seizures, status epilepticus, and EEG monitoring in post-anoxic brain damage. Our guest is Dr. Thomas Bleck. Dr. Bleck is the professor of neurological sciences, neurosurgery, internal medicine and anesthesiology at Rush University Medical Center, where he is a neurointensivist and the director of clinical neurophysiology. Additional Resources: Evidence-Based Guideline: Treatment of Convulsive Status Epilepticus in Children and Adults: Report of the Guideline Committee of the American Epilepsy Society: http://www2.soundphysicians.com/l/403342/2018-06-27/cxz5ng/403342/102465/Evidence_Based_Guideline_Treatment_of_Convulsive_Status_Epilepticus_in_Children_an.pdf Guidelines for the Evaluation and Management of Status Epilepticus: http://www2.soundphysicians.com/l/403342/2018-06-27/cxz5nb/403342/102461/Guidelines_for_the_evaluation_and_management_of_status_epilepticus..pdf Clinical classification of post anoxic myoclonic status: http://www2.soundphysicians.com/l/403342/2018-06-27/cxz5nd/403342/102463/Clinical_classification_of_post_anoxic_myoclonic_status.pdf Books Mentioned in This Episode: Tinker, Tailor, Soldier, Spy: A George Smiley Novel: https://www.amazon.com/Tinker-Tailor-Soldier-Spy-George-ebook/dp/B004RKXNDU/ref=sr_1_1?ie=UTF8&qid=1530020470&sr=8-1&keywords=tinker+soldier+le+carre

When it comes to managing patients with epilepsy, there isn't a one-size-fits-all approach. And it would be wrong to assume you could treat a woman the same way you would treat a man. There are a number of special considerations to keep in mind--especially birth control and pregnancy. Not to mention the increase risk of seizures during menses for some women. In this week's program, we revisit one of the earliest shows we put together in 2016 on the special considerations when it comes to women with epilepsy. Dr. Danielle Becker--an epileptologist at Penn--joins Jim Siegler for the discussion. Produced by James E. Siegler. Music courtesy of Josh Woodward. Sound effects by Mike Koenig and Daniel Simion. BrainWaves' podcasts and online content are intended for medical education only and should not be used for clinical decision making. Be sure to follow us on Twitter @brainwavesaudio for the latest updates to the podcast. IF YOU'RE TAKING YOUR NEUROLOGY BOARDS, and not sure how to prepare, check out the 2019 Penn Neurology Board Review Course here [https://upenn.cloud-cme.com/default.aspx?P=5&EID=54399]. BrainWaves' listeners get $150 off their enrollment fee using the promo code 'WAVES2019'. REFERENCES Meador K, Reynolds MW, Crean S, Fahrbach K and Probst C. Pregnancy outcomes in women with epilepsy: a systematic review and meta-analysis of published pregnancy registries and cohorts. Epilepsy Res. 2008;81:1-13. Meador KJ, Baker GA, Browning N, Cohen MJ, Bromley RL, Clayton-Smith J, Kalayjian LA, Kanner A, Liporace JD, Pennell PB, Privitera M, Loring DW and Neurodevelopmental Effects of Antiepileptic Drugs Study G. Breastfeeding in children of women taking antiepileptic drugs: cognitive outcomes at age 6 years. JAMA Pediatr. 2014;168:729-36. Veliskova J and Desantis KA. Sex and hormonal influences on seizures and epilepsy. Horm Behav. 2013;63:267-77. Herzog AG, Fowler KM, Smithson SD, Kalayjian LA, Heck CN, Sperling MR, Liporace JD, Harden CL, Dworetzky BA, Pennell PB, Massaro JM and Progesterone Trial Study G. Progesterone vs placebo therapy for women with epilepsy: A randomized clinical trial. Neurology. 2012;78:1959-66. Tauboll E, Sveberg L and Svalheim S. Interactions between hormones and epilepsy. Seizure. 2015;28:3-11. Crawford P. Best practice guidelines for the management of women with epilepsy. Epilepsia. 2005;46 Suppl 9:117-24. Reiter SF, Bjork MH, Daltveit AK, Veiby G, Kolstad E, Engelsen BA and Gilhus NE. Life satisfaction in women with epilepsy during and after pregnancy. Epilepsy Behav. 2016;62:251-257. Harden CL, Hopp J, Ting TY, Pennell PB, French JA, Hauser WA, Wiebe S, Gronseth GS, Thurman D, Meador KJ, Koppel BS, Kaplan PW, Robinson JN, Gidal B, Hovinga CA, Wilner AN, Vazquez B, Holmes L, Krumholz A, Finnell R, Le Guen C, American Academy of N and American Epilepsy S. Practice parameter update: management issues for women with epilepsy--focus on pregnancy (an evidence-based review): obstetrical complications and change in seizure frequency: report of the Quality Standards Subcommittee and Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and American Epilepsy Society. Neurology. 2009;73:126-32.

Dr. Thomas Seyfried joins us to talk about his book Cancer as a Metabolic Disease: On the Origin, Management, and Prevention of Cancer, and also to talk about his research at Boston College which focuses on mechanisms by which metabolic therapy manages chronic diseases such as epilepsy, neurodegenerative lipid storage diseases, and cancer. The metabolic therapies include caloric restriction, fasting, and ketogenic diets. This new concept has implications for the development of new non-toxic cancer therapies including the ketogenic diet, and experts in the cancer research field have praised this comprehensive study as one of science's hottest topics. Thomas N. Seyfried received his Ph.D. in Genetics and Biochemistry from the University of Illinois, Urbana, in 1976. He did his undergraduate work at the University of New England, where he recently received the distinguished Alumni Achievement Award. He also holds a Master’s degree in Genetics from Illinois State University. Thomas Seyfried served with distinction in the United States Army’s First Cavalry Division during the Vietnam War and received numerous medals and commendations. He was a Postdoctoral Fellow in the Department of Neurology at the Yale University School of Medicine and then served on the faculty as an Assistant Professor in Neurology. Other awards and honors have come from such diverse organizations as the American Oil Chemists Society, the National Institutes of Health, The American Society for Neurochemistry, and the Ketogenic Diet Special Interest Group of the American Epilepsy Society. Dr. Seyfried previously served as Chair, Scientific Advisory Committee for the National Tay-Sachs and Allied Diseases Association and presently serves on several editorial boards, including those for Nutrition & Metabolism, Neurochemical Research, the Journal of Lipid Research, and ASN Neuro, where he is a Senior Editor. Dr. Seyfried has over 150 peer-reviewed publications.

Dr. Rodrigo Quian Quiroga is a Professor and Director of the Centre for Systems Neuroscience at the University of Leicester in the United Kingdom. He is also an author of the books Borges and Memory, Principles of Neural Coding, Imaging Brain Function with EEG, and the recently published book The Forgetting Machine. Rodrigo enjoys getting out of the lab to do different activities to give his mind a break from thinking about experiments. In particular, he enjoys hanging out with his wife and kids, playing sports, and practicing Judo. Rodrigo is interested in understanding how memory works and how the brain works in general. He conducts experiments to determine how the neurons in our brain make us see, feel, make decisions, and remember the things we experience and learn in our lives. The memory research in Rodrigo’s lab investigates how memories are formed, stored, consolidated, and forgotten. Rodrigo received his undergraduate training in physics from the University of Buenos Aires in Argentina and was awarded his PhD in Applied Mathematics from the University of Luebeck in Germany. He was a postdoctoral fellow at the Research Center Juelich in Germany and he received a Sloan Fellowship to conduct research at the California Institute of Technology. Rodrigo also worked briefly at RIKEN in Japan and at the University of Nijmegen in The Netherlands. Rodrigo has received numerous awards and honors including the Royal Society Wolfson Research Merit Award, a Young Investigator Award from the American Epilepsy Society, and Rodrigo was also named one of 10 UK RISE Leaders in Science and Engineering in 2014. Rodrigo spoke with us about his experiences his career, research, and life.

Cancer is painted as a multi-faceted and complicated disease that has many forms. However, there seems to be one common theme in all cancers which plays a massive role in combating it. In this podcast, we delve into this mechanistic behavior of cancer cells. Bio: Thomas N. Seyfried received his Ph.D. in Genetics and Biochemistry from the University of Illinois, Urbana, in 1976. He did his undergraduate work at the University of New England, where he recently received the distinguished Alumni Achievement Award. He also holds a Master’s degree in Genetics from Illinois State University. Thomas Seyfried served with distinction in the United States Army’s First Cavalry Division during the Vietnam War and received numerous medals and commendations. He was a Postdoctoral Fellow in the Department of Neurology at the Yale University School of Medicine and then served on the faculty as an Assistant Professor in Neurology. Other awards and honors have come from such diverse organizations as the American Oil Chemists Society, the National Institutes of Health, The American Society for Neurochemistry, and the Ketogenic Diet Special Interest Group of the American Epilepsy Society. Dr. Seyfried previously served as Chair, Scientific Advisory Committee for the National Tay-Sachs and Allied Diseases Association and presently serves on several editorial boards, including those for Nutrition & Metabolism, Neurochemical Research, the Journal of Lipid Research, and ASN Neuro, where he is a Senior Editor. Dr. Seyfried has over 150 peer-reviewed publications and is the author of the book “Cancer as a Metabolic Disease: On the Origin, Management, and Prevention of Cancer (Wiley Press).” Time Stamps:  0:16 - News from Ketogeek 4:53 – Dr. Seyfried’s bio 7:25 – Dr. Seyfried’s journey to keto & low carb 8:22 – The origins of the Ketogenic Diet, the Charlie Foundation & Cancer Research 11:16 – How do you create a ketogenic diet? 12:32 – The glucose-ketone Index 14:24 – The power of ketones & cancer preventative mechanism 17:16 – Oncogenic Paradox and what causes cancer in the body? 19:33 – Tumor metastasis & dangers of carrying out a biopsy of the lump 21:46 – Moving from chemotherapy to a metabolic solution to cancer 23:52 – What challenges do you face as a cancer researcher? 27:02 – What’s your advice for future oncologists and medical students? 30:20 – Why does glucose & glutamine fuel cancer cells and resist cell death? 32:16 – Are there exceptions to the metabolic theory? 34:30 – Can cancer cells adapt to ketones? 36:55 – How do you figure out a medical procedure works? 40:24 – Is cancer a modern disease? 42:30 – Can you predict cancer & importance of CRP level? 45:38 – What does it mean to be “healthy mitochondria”? 47:06 – What kind of cancers are still giving us trouble? 48:18 – What biomarkers are affected by tumor growth? 51:37 – How do I talk to my oncologist about my tumor? 54:12 – How do I know I am doing the right thing? 56:49 – How can educational institutions embrace change? 59:09 – The health crises in cancer therapies. 1:01:49 – What precautions can cancer survivors take? 1:03:00 – Is coffee and alcohol an issue? 1:05:52 – What books would you recommend? 1:08:52 – What kind of conferences can people attend? 1:10:45 – Final Message 1:11:46 – Dr. Seyfried’s book “Cancer As a Metabolic Disease” 1:14:21 – Final Plug 1:15:23 – The common theme in all cancers and the problem with building nonprofits around different cancers 1:17:40 – Single Cause, Single Cure foundation Plugs: Dr. Thomas Seyfried: https://www.bc.edu/bc-web/schools/mcas/departments/biology/people/faculty-directory/thomas-seyfried.html Single Cause, Single Cure: https://www.foundationformetaboliccancertherapies.com/ Heads Up Health: https://www.headsuphealth.com/ Ketogeek: https://ketogeek.com/ Nutty Carnivore: https://ketogeek.com/pages/nutty-carnivore-diet Cancer As a Metabolic Disease (Book): https://www.amazon.com/Cancer-Metabolic-Disease-Management-Prevention/dp/0470584920 Tripping over the Truth (Book): https://www.amazon.com/Tripping-over-Truth-Overturning-Entrenched/dp/1603587292    

1) Featured Article: Quality improvement in neurology: Child neurology quality measure set2) Lesson of the Week: Update on chronic migraine risk factors, management, and treatmentThis Neurology® Podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the January 9, 2018, issue of Neurology. In the first segment, Dr. Adam Numis talks with Dr. Jeffrey Buchhalter and Dr. Anup Patel about their quality measure set executive summary article regarding child neurology. For the “Lesson of the Week” segment, Dr. Tesha Monteith speaks with Dr. Stephen Silberstein about chronic migraine.DISCLOSURES:Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section; has received speaker honorarium from LivaNova; and has received research support from American Academy of Neurology, Clinical Research Training Fellowship in Epilepsy, 2017-2019, and American Epilepsy Society, Research and Training Fellowships for Clinicians, 2017-2018.Dr. Bucchalter has served on advisory and safety monitoring boards for NIH, NINDS, Observational Safety Monitoring Board for NIH, and the Charlie Foundation; has received travel and speaker honoraria from AAN, Eisai Co. Ltd., Child Neurology Society, Lundbeck, and Upsher-Smith Labs; serves on the editorial board for Pediatric Neurology; has consulted in the past with Lundbeck Inc., Eisai Co. Ltd., UCB, and Upsher-Smith; and has received research support from Alberta Health Services.Dr. Patel has served on scientific advisory board for UCB Pharma; has served as book and associate editor for Journal of Child Neurology; has consulted for Greenwich Biosciences, LivaNova, and Supernus; and has received research support from Greenwich Biosciences, Brain Sentinel, Upsher Smith Pharmaceuticals, LivaNova, Pediatric Epilepsy Research Foundation (PERF), and American Academy of Neurology (AAN).Dr. Silberstein has served on scientific advisory boards for Alder, Allergan, Amgen, Avanir, eNeura, ElectroCore Medical, Medscape, Medtronic, Mitsubishi Tanabe, Neuralieve, NINDS, Pfizer, Supernus, Teva, Curelator, Depomed, Dr. Reddy's Laboratories, Lilly, and Trigemina; has served on editorial boards for Cephalalgia, Current Pain and Headache Reports, CNS Drugs, Topics in Pain Management, and Neurology; has consulted for Allergan, Amgen, eNeura, ElectroCore Medical, Mitsubishi Tanabe, Medtronic, Neuralieve, Pfizer, Supernus, and Teva; served on speaker's bureaus in the past for Allergan, Endo Pharmaceuticals, GlaxoSmithKline, Zogenix, and Merck; and has received research support from GlaxoSmithKline, Allergan, Merck, Novartis, NIH, Neurolieve, MAP, Endo, Amgen, ElectroCore, Avanir, NIH, AHS, and IHS.Dr. Monteith serves as an editorial advisory board member for Neurology Now and receives research support from the NIH.

How often do you call the plumber and say, "My faucet is leaking", and then the plumber REMOVES your faucet? Problem solved, right? Ironically, this simplistic approach works extremely well in a variety of epileptic conditions. In this week's show, Dr. Myriam Abdennadher and Danielle Becker comment on the protocol and efficacy for surgery in patients with drug-resistant epilepsy. Produced by James E. Siegler. Music by Little Glass Men, Montplaisir, Three Chain Links, and Squire Tuck. Voiceover by Isa Smrstik. BrainWaves' podcasts and online content are intended for medical education only and should not be used for clinical decision making. REFERENCES Jobst BC and Cascino GD. Resective epilepsy surgery for drug-resistant focal epilepsy: a review. JAMA : the journal of the American Medical Association. 2015;313:285-93. Spencer S and Huh L. Outcomes of epilepsy surgery in adults and children. The Lancet Neurology. 2008;7:525-37. Schwartz TH and Spencer DD. Strategies for reoperation after comprehensive epilepsy surgery. Journal of neurosurgery. 2001;95:615-23. Engel J, Jr., Wiebe S, French J, Sperling M, Williamson P, Spencer D, Gumnit R, Zahn C, Westbrook E, Enos B, Quality Standards Subcommittee of the American Academy of N, American Epilepsy S and American Association of Neurological S. Practice parameter: temporal lobe and localized neocortical resections for epilepsy: report of the Quality Standards Subcommittee of the American Academy of Neurology, in association with the American Epilepsy Society and the American Association of Neurological Surgeons. Neurology. 2003;60:538-47. Englot DJ, Wang DD, Rolston JD, Shih TT and Chang EF. Rates and predictors of long-term seizure freedom after frontal lobe epilepsy surgery: a systematic review and meta-analysis. Journal of neurosurgery. 2012;116:1042-8. DeGiorgio CM and Krahl SE. Neurostimulation for drug-resistant epilepsy. Continuum (Minneap Minn). 2013;19:743-55.

Despite so many highly publicized breakthroughs in medical science, cancer remains a formidable disease. Deaths from cancer are actually continuing to rise, at a rate of 3.5 to 4% each year. My interview today is with Dr. Thomas Seyfried. Dr. Seyfried believes cancer isn’t primarily caused by damage to the genes living in the nucleus of the cell, a widely held belief, but rather represents a problem of how cells produce energy from their mitochondria. Ultimately, this defective energy production leads to increased free radical production which may then go on to damage the DNA of the cell nucleus as a secondary event. What is so elegant and compelling about his theory is that it lends itself to a powerful interventional approach centered on simply shifting the energy source of the mitochondria to products derived from fat, as opposed to carbohydrates. Dr. Seyfried received his Ph.D. in Genetics and Biochemistry from the University of Illinois and also holds a Master’s degree in Genetics from Illinois State University He was a Postdoctoral Fellow in the Department of Neurology at the Yale University School of Medicine, and then served on the faculty as an Assistant Professor in Neurology. Prior to receiving full professorship, Dr. Seyfried was an Associate Professor in the Department of Biology at Boston College. Other awards and honors have come from such diverse organizations as the American Oil Chemists Society, the National Institutes of Health, The American Society for Neurochemistry, and the Ketogenic Diet Special Interest Group of the American Epilepsy Society. Dr. Seyfried previously served as Chair, Scientific Advisory Committee for the National Tay-Sachs and Allied Diseases Association and presently serves on several editorial boards, including those for Nutrition & Metabolism, Neurochemical Research, and the Journal of Lipid Research. Dr. Seyfried’s research program focuses on gene environmental interactions related to complex diseases, such as epilepsy, autism, brain cancer, and neurodegenerative diseases. Dr. Seyfried investigates many of these diseases from the perspective of, genetics, and energy metabolism. Much of his work, gratefully, also has direct translational benefit to the clinic. This is a somewhat science-based discussion, but hang in there as there are some critically important gems of information that we get from Dr. Seyfried. Finally, in the broadcast, Dr. Seyfried mentions a book on this subject that’s  geared to a less scientifically minded community. The book is entitled, Tripping Over the Truth, by Travis Christofferson.

In this episode, Amy Brooks-Kayal, MD, discusses acute seizure management. The conversation includes the importance of gathering a detailed history of a seizure event, identifying provocations of a seizure and options for anti-seizure and rescue medications. Dr. Brooks-Kayal is the Chief of the Pediatric Neurology, Co-Director of the Translational Epilepsy Research Program and past president of the American Epilepsy Society. In this episode: Responding to a patient's first seizure Importance of a detailed history of a seizure event Identifying provocations of a seizure Neurological examination Focal onset versus a generalized seizure Chances of seizure reoccurrence Anti-seizure and rescue medications Managing the anxiety of families Basic seizure safety Current research into pediatric epilepsy

The first seizure of life is a common presentation requiring a neurology consultation. In this episode, Dr. Brian Hanrahan of the University of Pittsburgh Medical Center, discusses his approach to counseling an adult patient with a first ever seizure, with a particular emphasis on driving safety. Produced by James E. Siegler. Music by Axletree, Josh Woodward, and Kevin McLeod. Voiceover by Emma Smrstik. BrainWaves' podcasts and online content are intended for medical education only and should not be used for clinical decision making. Think responsibly. Podcasts are no excuse NOT to treat a patient who is seizing. REFERENCES Maganti RK and Rutecki P. EEG and epilepsy monitoring. Continuum (Minneap Minn). 2013;19:598-622. Smith SJ. EEG in the diagnosis, classification, and management of patients with epilepsy. Journal of neurology, neurosurgery, and psychiatry. 2005;76 Suppl 2:ii2-7. Sofat P, Teter B, Kavak KS, Gupta R and Li P. Time interval providing highest yield for initial EEG in patients with new onset seizures. Epilepsy Res. 2016;127:229-232. Krumholz A, Shinnar S, French J, Gronseth G and Wiebe S. Evidence-based guideline: Management of an unprovoked first seizure in adults: Report of the Guideline Development Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology. 2015;85:1526-7. Richards KC. Patient page. The risk of fatal car crashes in people with epilepsy. Neurology. 2004;63:E12-3. Krumholz A. Driving issues in epilepsy: past, present, and future. Epilepsy Curr. 2009;9:31-5. Temkin NR, Dikmen SS, Wilensky AJ, Keihm J, Chabal S and Winn HR. A randomized, double-blind study of phenytoin for the prevention of post-traumatic seizures. The New England journal of medicine. 1990;323:497-502. Thompson K, Pohlmann-Eden B, Campbell LA and Abel H. Pharmacological treatments for preventing epilepsy following traumatic head injury. The Cochrane database of systematic reviews. 2015:CD009900. Deutschman CS and Haines SJ. Anticonvulsant prophylaxis in neurological surgery. Neurosurgery. 1985;17:510-7. van Breemen MS, Wilms EB and Vecht CJ. Epilepsy in patients with brain tumours: epidemiology, mechanisms, and management. The Lancet Neurology. 2007;6:421-30. Hemphill JC, 3rd, Greenberg SM, Anderson CS, Becker K, Bendok BR, Cushman M, Fung GL, Goldstein JN, Macdonald RL, Mitchell PH, Scott PA, Selim MH, Woo D, American Heart Association Stroke C, Council on C, Stroke N and Council on Clinical C. Guidelines for the Management of Spontaneous Intracerebral Hemorrhage: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke; a journal of cerebral circulation. 2015;46:2032-60.

There's more to epilepsy than AED titration. (Shocking, I know.) Especially in women, management is undeniably complex. For example, the same enzymatic machinery used to metabolize AEDs is also used to break down estrogen-containing oral contraceptives--an interaction that could literally open a Pandora's box of complications. These and other issues affecting the management of women with epilepsy are addressed by Dr. Danielle Becker in this week's BrainWaves podcast. BrainWaves podcasts and online content are intended for medical education only and should not be used to guide medical decision making in routine clinical practice. Any cases discussed in this episode are fictional and do not contain any patient health identifying information. This episode was vetted and approved by Danielle Becker. REFERENCES 1. Meador K, Reynolds MW, Crean S, Fahrbach K and Probst C. Pregnancy outcomes in women with epilepsy: a systematic review and meta-analysis of published pregnancy registries and cohorts. Epilepsy Res. 2008;81:1-13. 2. Meador KJ, Baker GA, Browning N, Cohen MJ, Bromley RL, Clayton-Smith J, Kalayjian LA, Kanner A, Liporace JD, Pennell PB, Privitera M, Loring DW and Neurodevelopmental Effects of Antiepileptic Drugs Study G. Breastfeeding in children of women taking antiepileptic drugs: cognitive outcomes at age 6 years. JAMA Pediatr. 2014;168:729-36. 3. Veliskova J and Desantis KA. Sex and hormonal influences on seizures and epilepsy. Horm Behav. 2013;63:267-77. 4. Herzog AG, Fowler KM, Smithson SD, Kalayjian LA, Heck CN, Sperling MR, Liporace JD, Harden CL, Dworetzky BA, Pennell PB, Massaro JM and Progesterone Trial Study G. Progesterone vs placebo therapy for women with epilepsy: A randomized clinical trial. Neurology. 2012;78:1959-66. 5. Tauboll E, Sveberg L and Svalheim S. Interactions between hormones and epilepsy. Seizure. 2015;28:3-11. 6. Crawford P. Best practice guidelines for the management of women with epilepsy. Epilepsia. 2005;46 Suppl 9:117-24. 7. Reiter SF, Bjork MH, Daltveit AK, Veiby G, Kolstad E, Engelsen BA and Gilhus NE. Life satisfaction in women with epilepsy during and after pregnancy. Epilepsy Behav. 2016;62:251-257. 8. Harden CL, Hopp J, Ting TY, Pennell PB, French JA, Hauser WA, Wiebe S, Gronseth GS, Thurman D, Meador KJ, Koppel BS, Kaplan PW, Robinson JN, Gidal B, Hovinga CA, Wilner AN, Vazquez B, Holmes L, Krumholz A, Finnell R, Le Guen C, American Academy of N and American Epilepsy S. Practice parameter update: management issues for women with epilepsy--focus on pregnancy (an evidence-based review): obstetrical complications and change in seizure frequency: report of the Quality Standards Subcommittee and Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and American Epilepsy Society. Neurology. 2009;73:126-32.

Dr. Cass Ingram is a nutritional physician who received a B.S. in biology and chemistry from the University of Northern Iowa (1979) and a D.O. from the University of Osteopathic Medicine and Health Sciences in Des Moines, IA (1984). Dr. Ingram has since written over 20 books on natural healing and is recognized as one of North America's leading experts on the health benefits and disease fighting properties of wild medicinal spice extracts. A popular media personality, he has appeared on over 5,000 radio and TV shows. He now travels the world promoting perfect health – the natural way. An interview with medicinal herb and spice expert Dr. Cass Ingram author of The Cannabis Cure Study: Neurologist uses cannabis to stop or reduce seizures in 261 epileptic kids Researchers are burning the midnight oil to discover the many wonderful medicinal properties of the cannabis plant – a rich source of important chemical compounds called cannabinoids which are linked to the healthy function of virtually every organ and system in the human body. In a clinical study recently presented to members of the American Epilepsy Society, Dr. Orrin Devinski, Professor of Neurology, Neurosurgery, and Psychiatry at New York University School of Medicine, was able to demonstrate how one powerful cannabinoid known as CBD (short for cannabidiol) was able to significantly reduce or halt seizures and convulsions more than two hundred epileptic children. “The study involved some 313 epilepsy victims, all children, who were given a medically purified form of the CBD cannabinoid and monitored over a 90-day period. Of the 261 children who remained in the study, virtually all had a response that was astounding: a 50% reduction in seizures or convulsions. Furthermore, 10% of the children became seizure-free during the treatment period,” says Dr. Cass Ingram, author of the book The Cannabis Cure. Dr. Ingram, an expert in the medicinal properties of cannabis and other plants, says the historical evidence supporting the use of cannabinoid-rich herbs such as cannabis, holy basil, wild sage, wild rosemary, and wild oregano to treat epilepsy and nervous disorders is vast. “A wide range of infectious agents can be involved in the causation of seizure syndromes, including viruses, molds, fungi, worms, protozoa, and other parasites, and all are capable of invading brain tissue where they lay eggs or create cysts which place pressure on brain centers, leading to seizures,” says Dr. Ingram. “The cannabinoid rich-plants and their oils are especially suited to attack these hidden invaders and quickly inactivate them.” In terms of pure antiseptic properties, Dr. Ingram says wild oregano oil has been documented as the most potent natural germ and parasite killer known. “It is particularly effective against viruses, bacteria, molds, and yeasts,” says Dr. Ingram. “As published in the scientific literature, oregano’s main action is against protozoans: amoebas, blastocysts, cryptosporidium, the malarial parasite, and giardia. It is also an ideal agent for brain infections of any type, as many of its components penetrate the blood-brain barrier.” Is there any evidence that wild oregano by itself is a remedy for seizures? “Historically, it was used precisely for precisely that purpose,” says Dr. Ingram. “It was the ancient Greeks who used it successfully for treating seizure syndromes, but they also used it as a cure for other head-related syndromes such as migraines. In an animal study published in Epilepsy Research and Treatment, researchers found that the essential oil of wild oregano, rich in the active ingredient carvacrol, prevented seizures significantly. So did other essential oils, including oils of mint, peppermint, basil, rosemary, and lavender.” #insomnia #epilepsy #autism #depression #stress #pain #cancer #heart #medical #marihuana #medicalmarihuana #hemp #hempanol

In this episode of Hallway Conversations, Epilepsy.com Editor-In-Chief Dr. Joseph Sirven interviews Tracy Glauser, MD, PhD, Associate Director of the Cincinnati Children's Research Foundation, Director of Comprehensive Epilepsy Center, Co-Director, Genetic Pharmacology Service and Professor at the University of Cincinnati Department of Pediatrics. They will discuss new status epilepticus guidelines. This content is created through a partnership between the Epilepsy Foundation and American Epilepsy Society.

Epilepsy.com Editor-In-Chief Dr. Joseph Sirven interviews Tricia Ting MD, Associate Professor of Neurology and Director of Investigational Drug Trials in Epilepsy at the University of Maryland Medical Center. They will discuss the results of FDA research about generic antiepileptic drugs. This content is created through a partnership between the Epilepsy Foundation and American Epilepsy Society.

1) Time from convulsive status epilepticus onset to anticonvulsant administration in children and 2) Topic of the month: Voices of encephalitis. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. John Mytinger interviews Dr. Tobias Loddenkemper about his paper on time from convulsive status epilepticus onset to anticonvulsant administration in children. Dr. James Addington is reading our e-Pearl of the week about cannabis in epilepsy. In the next part of the podcast Dr. Lara Marcuse interviews Stephen Haslett about the topic of herpes simplex virus encephalitis. The participants had nothing to disclose except Dr. Loddenkemper and Addington.Dr. Loddenkemper performs video EEG long term monitoring, EEGs and other electrophysiological studies at Boston Children's Hospital (20% effort); evaluates pediatric neurology patients; serves on the Laboratory Accreditation Board for Long Term (Epilepsy and Intensive Care Unit) Monitoring, on the Council of the American Clinical Neurophysiology Society, on the American Board of Clinical Neurophysiology; serves as an Associate Editor for Seizure serves as Contributing Editor for Epilepsy Currents; serves as an Associate Editor for Wyllie's Treatment of Epilepsy 6th edition; is part of pending patent applications to detect seizures and to diagnose epilepsy; receives research support from the American Epilepsy Society, the Epilepsy Foundation of America, the Epilepsy Therapy Project, PCORI, the Pediatric Epilepsy Research Foundation, Cure, Danny-Did Foundation, HHV-6 Foundation, Lundbeck Inc., Eisai Inc., and Upsher-Smith Laboratories, Inc.Dr. Addington serves on the editorial team for the Neurology® Resident and Fellow Section.

Epilepsy.com Editor-In-Chief Dr. Joseph Sirven interviews Dr. Jacqueline French, chief science officer of the Epilepsy Foundation, about newly released guidelines for the treatment of first seizures. This content is created through a partnership between the Epilepsy Foundation and American Epilepsy Society.

Epilepsy.com Editor-In-Chief Dr. Joseph Sirven interviews Dr. Elson So, past president of the American Epilepsy Society, about his 2014 Presidential Symposium. The topic of the symposium was "Electrophysiological Biomarkers: Spatial and Temporal Prediction of Epilepsy and Seizures." An international competition using the wisdom of crowds has developed computer algorithms to detect, predict, and ultimately prevent epileptic seizures. Winners were announced at the AES 68th Annual Meeting in Seattle during the Presidential Symposium. This content will be created through a partnership between the Epilepsy Foundation and American Epilepsy Society.

Guest // Thomas Seyfried, PhDHost // Toni Bark, MDHalf of men and one-third of women will receive a cancer diagnosis sometime during their lives. Increasingly, more patients are declining conventional treatment. They are interested in a different kind of approach to cancer management and prevention.. one that is more cutting edge and incorporates the latest research.If we can understand what cancer is, what feeds it, and why metastasis happens, then we can find and apply more effective strategies to shrink (and hopefully eliminate) tumors.Meet Professor Thomas Seyfried. He is a biochemical geneticist who has been investigating the lipid biochemistry of cancer for thirty years. His pioneering research expands on Otto Warburg’s groundbreaking theory that cancer is a disease of energy metabolism. With this framework, he’s able to explain the relationship between cancer and inflammation, vascularization, cell death, drug resistance, and genomic instability. Discussion topics during today’s show include:How does this view differ from the direction in which much of current research and funding is heading? (i.e., genetics)Is the controversy largely a matter of cause and effect (i.e., mitochondrial respiration and genetic damage)?What has been the response of the scientific community?Where is the research heading? (i.e., mouse to man, clinical trials?)What is the ketogenic diet and how is it implemented? How does this differ when applied to children?What is the Press-Pulse metabolic strategy for cancer management?If you have questions, be sure to send them before the show or meet up with us on the blog afterwards to discuss.Thomas Seyfried, PhD focuses on gene environmental interactions related to complex diseases, such as epilepsy, autism, brain cancer, and neurodegenerative (the GM1 and GM2 gangliosidoses) diseases. He investigates many of these diseases from the perspective of, genetics, lipidomics, and energy metabolism. Tom received his Ph.D. in Genetics and Biochemistry from the University of Illinois, Urbana, in 1976. He  was an Assistant Professor in Neurology at Yale University School of Medicine. Tom has received awards from the NIH, The American Society for Neurochemistry, and the Ketogenic Diet Special Interest Group of the American Epilepsy Society. He was Chair, Scientific Advisory Committee for the National Tay-Sachs and Allied Diseases Association and serves on several editorial boards, for Nutrition & Metabolism, Neurochemical Research, the Journal of Lipid Research, and ASN Neuro. Read more about his work here.

In this episode of Epilepsy.com's Hallway Conversations, Dr. Joseph Sirven, Professor of Neurology at Mayo Clinic Arizona and Editor-in-Chief of Epilepsy.com, interviews Nathan Fountain, MD, Chair of the Epilepsy Foundation's Professional Advisory Board, and Paul Van Ness, MD, Director of UT Southwestern Medical Center's Epilepsy Program. They will be discussing epilepsy quality measures. Dr. Fountain and Dr. Van Ness are the co-chairs of the American Academy of Neurology's Epilepsy Quality Measures Committee. This interview is part of the Epilepsy Foundation's partnership with the American Epilepsy Society.

1) Early epileptiform abnormalities and 2) Topic of the month: Evaluation of polyneuropathy. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Mark Quigg with Drs. Moushin Shafi and Brandon Westover about their paper on absence of early epileptiform abnormalities. Dr. Jennifer Fugate is reading our e-Pearl of the week about Doral midbrain syndrome. In the next part of the podcast Dr. Ted Burns interviews Drs. Michelle L. Mauermann and P. James Dyck about evaluation of the chronic, axonal polyneuropathy. The participants had nothing to disclose except Drs. Quigg, Shafi, Fugate, Burns and Mauermann.Dr. Quigg receives royalties from the publication of the book EEG Pearls; has a patent for actigraphy system for seizure characterization and receives research support from the NIH.Dr. Shafi performs EMG and cEEG monitoring studies in his epilepsy practice (35% effort); receives honoraria from (1) J. Kiffin Penry Epilepsy Minifellowship - reimbursement for travel, conference accommodations and food (2) American Epilepsy Society Fellows Program - funds for travel and attendance at 2011 American Epilepsy Society conference; and receives research support from (1) National Center for Research Resources: Harvard Clinical and Translational Science Center and the Center for Integration of Medicine and Innovative Technology and is funded by the NIH. Dr. Fugate serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Ted Burns serves as Podcast Editor for Neurology®; performs EMG studies in his neuromuscular practice (35% effort); and has received research support for consulting activities with CSL Behring and Alexion Pharmaceuticals.Dr. Mauermann receives research support from Pfizer Inc and the NIH.

Joyce welcomes Dr. Brien Smith, chairman of the board of the national Epilepsy Foundation; Dr. Frances Jensen, president of the American Epilepsy Society; and Joan Austin, Ph.D., R.N., FAAN, a distinguished professor emerita at the Indiana University School of Nursing in Indianapolis and a consultant for the Intramural Program of the National Institute of Nursing Research at the National Institutes of Health (NIH). They will be discussing the latest research findings on the treatment of epilepsy as published in the book, Epilepsy across the Spectrum published by the Institute of Medicine of The National Academies.